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One of the most common hallmarks of cancer is dysregulation of cellular apoptotic 
processes.  A comprehensive knowledge of the underlying mechanisms of the apoptotic 
machinery is vital for the identification of new drug targets and the development of 
innovative agents that stimulate the cell death process in cancer cells.  Studies have 
shown that the lysosomal protease cathepsin D is important in the extrinsic apoptotic 
pathway stimulated by the death receptor ligands for TNFR1 and FAS, as well as by 
oxidative stress and the protein kinase C inhibitor staurosporine.  To date, the role of 
cathepsin D in the chemotherapy-induced apoptotic pathway has not been characterized.  
This project examined the role of the lysosomal protease cathepsin D in chemotherapy-
induced apoptosis of HeLa and U937 cells.  The data demonstrated that following 
stimulation of U937 cells with the chemotherapy drug VP-16, cathepsin D was released 
into the cytosol approximately 4 hours after drug treatment.  This release was selective 
for cathepsin D, as cathepsin B and the lysosomal markers LAMP and β-hexosaminidase 
were not released into the cytosol following VP-16 treatment.  Inhibitors of caspases and 
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cathepsin D had no effect on cathepsin D release, demonstrating that cathepsin D release 
occurred independently of caspase and cathepsin D activities.  Downregulation of 
cathepsin D expression in U937 and Hela cells using siRNA was found to inhibit cell 
death resulting from a variety of stimuli, including death receptor ligands, oxidative 
stress, PKC inhibitors, and importantly, chemotherapy drugs.  In addition, U937 and 
HeLa cells expressing cathepsin D siRNA exhibited delayed cytochrome c release and 
caspase-3 activation following VP-16 treatment.   Moreover, isolated mitochondria from 
wild-type U937 cells released cytochrome c in response to cytosolic extracts that were 
treated with cathepsin D, suggesting that cathepsin D acts on a cytosolic factor to induce 
cytochrome c release.  Inhibition of caspases had no impact on cytochrome c release 
provoked by cathepsin D-cleaved cytosolic extract, demonstrating that caspases are not 
mediators of cathepsin D-induced cytochrome c release.  Taken together, these results 
demonstrate that cathepsin D is an important component of the apoptotic pathway and 
that it acts via an intermediary cytosolic factor to promote cytochrome c release and 
caspase activation during chemotherapy-induced apoptosis. 
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 1. INTRODUCTION 
1.1. CANCER 
It is estimated that in the year 2005, over 1.3 million new cases of cancer will be 
diagnosed in the United States.1  Cancer is the cause of death for 1 in 4 Americans, and is 
second only to heart disease in leading causes of death in the U.S.2  The economic impact 
of cancer is staggering; the National Institutes of Health estimate that overall costs for 
medical and morbidity-related cancer concerns were almost $190 billion in 2004.3  
Cancer is not a disease in and of itself; instead, it is, as defined by the National Cancer 
Institute, “a group of diseases in which abnormal cells divide without control.4”  
Proliferation of abnormal cells is dangerous because not only do they reproduce in 
defiance of their normal restraints, but they invade and utilize resources needed for 
growth of normal cells [1].  Metastatic cells develop by gradually acquiring tumor-
specific genotypic mutations, leading to dysfunction of important cellular processes.  
While the patterns of genetic mutation may differ between the more than 100 distinct 
human cancer types, it is acknowledged that most cancer cells possess six general 
alterations in cellular physiology that allow them to surmount cellular anti-cancer defense 
mechanisms: “self-sufficiency in growth signals, insensitivity to growth inhibitory 
(antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
                                                 
1 2 3 American Cancer Society, Cancer Statistics and Figures 2005 (www.cancer.org) 
 
 
 
 
4 National Cancer Institute, US National Institutes of Health (www.cancer.gov) 
potential, sustained angiogenesis, and tissue invasion and metastasis.”[2]  These six 
common traits serve as targets for development of novel anti-cancer drugs.  With this in 
mind, it is necessary to understand the mechanisms by which cancer cells can deregulate 
themselves to promote their own rapid growth and immortality.   
A major concern regarding metastatic cells is that they often have surmounted the 
cellular signals that target them for cell death.  Chemotherapeutic agents are designed to 
elicit cell death in tumor cells.  The work in this project examines the role of a novel 
proteolytic enzyme in chemotherapy-induced apoptosis.   
 
1.2. APOPTOSIS 
One of the major cellular safeguards against aberrant growth of abnormal cells is 
programmed cell death, commonly known as apoptosis.  In order to maintain homeostasis 
of cell numbers in normal tissues, the ratio of cell proliferation to cell death must remain 
constant over time.  In cancers, genetic aberrations disturb that balance by promoting 
production of oncogenes that stimulate uncontrolled cell proliferation, inhibit cell death, 
or both.  It is critical that the biochemical pathways that render cancer cells resistant to 
apoptosis are understood so that treatments that target these pathways can be developed. 
 
1.2.1. DEFINITION  AND  CHARACTERISTICS  OF  APOPTOSIS 
Kerr et al. [3] coined the Greek term ‘apoptosis’ for programmed cell death, which 
translates as “falling leaves”.  Much as leaves falling from a tree die a characteristic  
death and are reabsorbed into the earth because they also are no longer necessary, 
apoptotic cells die via unique processes, and are reabsorbed because they are no longer 
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necessary and must make room for new cells.  Apoptosis is scientifically defined as the 
cellular morphological process leading to deliberate controlled self-destruction [4].  
Apoptosis plays a critical role in regulation and maintenance of cell homeostasis as 
well as a vital function in development.  In the human body, mitosis produces about 
100,000 cells every second, and to maintain homeostasis, an equal number of cells are 
eliminated [5].  During organ and limb development, apoptosis mediates digit sculpting 
by removing interdigital mesenchymal tissue between fingers and toes.  Massive 
apoptosis also contributes to the deletion of unnecessary organelles and the construction 
of hollow structures during development [6].  Additionally, apoptosis is fundamental in 
the removal of cells that have sustained radiation- or drug-incurred DNA damage.  
Failure of these damaged cells to self-destruct can result in accumulation and 
proliferation of cells with genetic mutations.  Therefore, metastatic cells that exhibit 
resistance to apoptosis are extremely dangerous.    
During apoptosis, several morphological changes occur that distinguish the 
apoptotic process from other cell death processes, such as necrosis.  First, the cell shrinks, 
becomes detached from neighboring cells, and loses its rigid shape.  During this process, 
the plasma membrane remains intact [7].  Also, chromatin condenses to very dense 
structures and migrates to the plasma membrane while activated nuclear DNase enzymes 
cleave DNA into a characteristic “apoptotic ladder” [8, 9].  Phosphatidylserine, which is 
normally localized to the interior of the plasma membrane, becomes exposed on the 
outside of the membrane, and the plasma membrane begins to “bleb”, or release small 
membrane-bound vesicles [10, 11].  These vesicles, which contain cytosol, engulfed 
vesicles, and chromatin, are termed apoptotic bodies; they are rapidly engulfed by 
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macrophages and eliminated without initiation of an inflammatory response [8].  Figure 
1.1 summarizes the morphological changes associated with apoptosis that differentiate 
the process from other forms of cell death. 
 
1.2.2. APOPTOTIC  PATHWAYS 
In addition to the morphological changes that occur during the apoptotic process, a 
complex intracellular signaling network is initiated by a variety of apoptotic stimuli from 
inside or outside the cell.  These stimuli include, but are not limited to, developmental 
death signals, stimulation of cell surface death receptors, deprivation of survival signals, 
or DNA damage incurred from chemotherapy drugs or radiation.  There are two distinct 
apoptotic pathways that ultimately end in cell death, and though cross-talk between the 
pathways does occur, apoptotic stimuli typically initiate either one or the other.   The 
extrinsic pathway, or death receptor-mediated apoptotic pathway, is evoked upon 
stimulation of death receptors in the tumor necrosis factor receptor family.  The intrinsic 
pathway, or mitochondrial apoptotic pathway, is evoked by stimuli that cause DNA 
damage or internal damage to the cell.  This section will discuss the differences between 
the intrinsic and extrinsic apoptotic pathways. 
 
1.2.2.1.  DEATH  RECEPTOR-MEDIATED  APOPTOSIS 
The extrinsic death receptor-mediated apoptosis pathway is stimulated by ligand 
binding to members of the tumor necrosis factor receptor superfamily including TNFR-1, 
Fas/CD95, and TNF-related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5 
[12, 13].  As a safeguard against inadvertent receptor activation, trimerization of death 
 4
  
 
Type of Cell Death Morphological Features 
Apoptosis Cell shrinking 
 Plasma membrane blebbing 
 Fragmentation of DNA to form “Ladder” 
 Externalization of phosphatidylserine 
 Chromatin condensation 
 Formation of apoptotic bodies 
 No induction of inflammatory response 
  
Necrosis Cell swelling 
 Precipitation of cytoplasmic contents  
 Induction of inflammatory response  
 
Figure  1.1.  Morphological characteristics of cell death 
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receptors is required for activation.  Binding of extracellular trimeric ligands to TNF 
receptors stimulates receptor activation by bringing three death receptors in close 
proximity, whereupon they form an active, trimerized death signaling complex [8, 11].  
In their cytoplasmic tails, death receptors contain a conserved Death Domain (DD) that, 
when trimerized, leads to recruitment of death adaptor proteins such as TRADD (in the 
case of TRAIL) and FADD (in the case of Fas ligand) [13, 14].  Although death domains 
are absolutely essential for the transmission of apoptotic signals via the death receptor 
pathway, little is known about their function except that they have an extremely high 
propensity to form hetero- and homo-oligomers.  The adaptor proteins themselves contain 
death domains that have a high affinity for active membrane-bound death domains.  The 
conglomeration of trimerized ligand, receptor, and adaptor proteins is known as the 
death-inducing signaling complex (DISC) [15].  In addition to their N-terminal death 
domains, death adaptor proteins also contain C-terminal Death Effector Domains 
(DEDs).  The N-terminal region of the zymogen form of caspase-8 protease contains a 
DED that binds with high affinity to the DISC [16].  Recruitment of procaspase-8 
molecules to the DISC brings them in close proximity to each other, where they have the 
capacity to autoactivate via a process termed “proximity-induced autoactivation”.  The 
activated caspase-8 then cleaves and activates the executioner caspase, caspase-3.  
Activation of executioner caspases leads to downstream proteolysis of cellular substrate 
proteins that will be discussed momentarily [11].  In Figure 1.2, a model of death 
receptor-mediated apoptosis is outlined.  
 6
  
 
 
 
Figure  1.2.  The extrinsic death receptor-mediated apoptotic pathway. The death 
receptor-mediated pathway is initiated by death ligands such as TNF-α, TRAIL, or 
Fas/APO-1.  Trimerization of the receptors is required for formation of the death-
inducing signaling complex (DISC).  Trimeric death domains (DDs) recruit adaptor 
molecules with death effector domains (DEDs) that subsequently recruit procaspase-
8.  See text for details. 
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1.2.2.2. MITOCHONDRIA-MEDIATED  APOPTOSIS 
The intrinsic mitochondrial-mediated apoptosis pathway is initiated by signals that 
originate within the cell, such as from DNA damage induced by chemotherapeutic agents 
or radiation.  These agents induce mitochondrial dysfunction by provoking a reduction in 
mitochondrial membrane potential and release of mitochondrial apoptogenic proteins into 
the cytosol [8, 17].  One such apoptogenic factor is cytochrome c.  Cytochrome c 
functions in normal cells as an electron carrier in the mitochondrial respiratory electron-
transport chain [1, 18].  During apoptosis, cytochrome c is released from mitochondria 
into the cytosol.  As mentioned previously, multiple safeguards prevent accidental 
initiation of apoptosis; therefore, cytochrome c release is tightly regulated.  Regulation is 
controlled in part by the Bcl-2 family of apoptosis regulatory proteins, which contains 
both pro- and anti-apoptotic members.  Following an apoptotic stimulus, some pro-
apoptotic factors are activated via oligomerization (e.g. Bax and Bak) or via cleavage 
(e.g. Bid).  Anti-apoptotic factors (e.g. Bcl-2 and Bcl-XL) are inactivated via cleavage or 
via binding of regulatory proteins that suppresses their inhibitory function [19].  Bcl-2 
and Bcl-XL reside in the outer mitochondrial membrane and inhibit cytochrome c release.  
Figure 1.3 contains a current list of known Bcl-2 family members.  In addition to 
regulation by the Bcl-2 family, Boehning et al. [20] and Mattson et al. [21] have also 
shown that release of cytochrome c from the mitochondria requires calcium efflux from 
the endoplasmic reticulum.       
Through hydrolysis of dATP, cytosolic cytochrome c binds to and provokes 
oligomerization of the monomeric adaptor molecule Apaf-1 [22].  The cytochrome c- 
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  Bcl-2 family members  
Anti-Survival Bad Bak 
 Bax Bcl-G 
 Bfk Bid 
 Bik Bim 
 Blk Bmf 
 BNip/3 Bok 
 BPR Egl-1 
 HRK/DP5 Mil-1 
 Nip 1/3 Noxa 
 Puma  
   
Pro-Survival A1 Bcl-2 
 Bcl-W Bcl-XL 
 Boo/Diva Mcl-1 
 Bcl-XS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  1.3.  The Bcl-2 protein family 
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Apaf-1 complex then binds the zymogen form of caspase-9, forming a complex known as 
the apoptosome.  Formation of the apoptosome evokes catalytic activation of caspase-9, a 
process necessary for chemotherapy-induced apoptosis.  Once activated, caspase-9 
cleaves and activates executioner caspases, including caspase-3 and -7.  Activation of the 
executioner caspases culminates in cell death [22].  Figure 1.4 depicts a representation of 
the intrinsic apoptosis pathway. 
    
1.3. PROTEASES  IN  APOPTOSIS 
Signaling cascades that occur during both the intrinsic and extrinsic apoptosis 
pathways ultimately culminate in the activation of proteolytic enzymes that are 
responsible for the degradation of proteins and concomitant destruction of the cell.  These 
proteases, known as caspases, are the most well-characterized apoptotic enzymes, as they 
are vital for apoptotic execution following most stimuli.  This section addresses the role 
of caspases in the apoptotic pathway as they are currently understood. 
  
1.3.1. CASPASES 
Caspases are cytosolic cysteine proteases; specifically, their catalytic activity is 
dependent on a cysteine residue in a highly conserved QACXG sequence (with X being 
R,Q, or G) [23, 24].  Caspase-mediated cleavage is also highly specific, always following 
an aspartate residue found within a common motif (e.g. DEVD or IETD).  The 
proenzyme forms of all caspases contain an N-terminal prodomain, followed by a large 
and a small subunit.  During activation, the prodomain is cleaved and degraded, while the  
 10
  
 
 
 
 
Figure  1.4. The intrinsic mitochondrial apoptosis pathway. The intrinsic 
mitochondrial pathway can be initiated by DNA damage caused by 
chemotherapeutic agents, radiation, etc.  Mitochondria are stimulated to release 
cytochrome c, which complexes with Apaf-1 and procaspase-9 to form the 
‘apoptosome’, which initiates activation of caspase-9 and the caspase cascade. 
See text for full details. 
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large and small subunits heterodimerize to form a complex containing two large subunits 
and two small subunits [23].   
The caspase family consists of two subtypes: the initiators and the executioners.  
The initiator caspases are caspases-2 and -9 (for the intrinsic pathway) and caspases-8 
and -10 (for the extrinsic pathway). They are activated following binding of ligand to 
death receptor or following cytochrome c release and apoptosome complex formation 
[25].  Activated initiator caspases cleave and activate executioner caspases (caspases-3,   
-6, -7, and -12), so called because they elicit cell death through cleavage of substrates that 
are critical to the normal function of the cell.  Initiator caspases differ structurally from 
the executioner caspases in that they have a very long prodomain that contains essential 
sequences for adaptor binding, while the prodomains of executioner caspases are short 
and act solely to inhibit caspase activation [23, 25]. 
Caspases are an integral part of the apoptotic cascade because they cleave over 60 
substrate proteins that are necessary for normal cellular function.  This extensive list of 
substrates includes proteins necessary for DNA metabolism (caspase-activated DNase), 
cytoskeletal scaffold proteins (lamins, gelsolin), cell cycle regulators (Cdk inhibitors), 
repair and housekeeping proteins (poly-ADP-ribose polymerase (PARP)), and signaling 
molecules (MEKK1, MAP3Ks) [17, 25-27].  Additionally, both pro- and anti-apoptotic 
members of the Bcl-2 family that are activated early in apoptosis serve as downstream 
caspase substrates.  Caspase-mediated cleavage of the Bcl-2 proteins functions as part of 
a positive feedback loop to further enhance caspase activity and accelerate the cell death 
process [23, 25, 26].  Figure 1.5 comprises a partial list of caspase substrates relevant to 
my study. 
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 Caspase Substrate Function of Substrate in Normal Cells 
PARP DNA repair enzyme 
DNA-PKcs DNA double-strand break repair 
Protein kinase C Cleaved to active form in apoptosis 
Lamins Nuclear envelope proteins 
Fodrin Membrane-assoc. cytoskeletal protein 
Rb Cell cycle regulator 
D4-GDP dissociation inhibitor Rho GTPase inhibitor 
IL-1β Proinflammatory cytokine 
Gelsolin Activated during apoptosis to degrade actin 
Bcl-2 family members Aid in apoptotic progression 
Other caspases Aid in apoptotic progression 
Inhibitor of caspase-activated DNase Releases DNase during apoptosis 
Figure  1.5.  Examples of caspase substrate proteins and their functions. 
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Because caspases play such a vital role in apoptosis, great efforts have been 
invested in elucidating their mechanistic role in apoptosis.  However, much evidence has 
arisen to suggest that other protease families also play an active role in apoptosis.  The 
cathepsin proteases are one such family.  Cathepsins were overlooked for many years 
because their residence in the lysosomal compartment appeared to isolate them from 
apoptotic processes in the cytosol and mitochondria.  It is now known, however, that 
cathepsins are not alienated from cell death signaling cascades; in fact, some of them play 
a noteworthy role in cell death induced by various stimuli.  Before expounding on the 
role of lysosomal proteases in apoptosis, however, the role of the lysosomal compartment 
in normal cells will be discussed. 
 
1.4. FUNCTION  OF  THE  LYSOSOMES  IN  NORMAL  CELLS 
Proteins that have been targeted for degradation are sent to the lysosomes, thus 
making the lysosomal compartment a cellular “garbage disposal”.  The lysosomal 
compartment contains about 40 different types of acid hydrolases, comprised of 
proteases, nucleases, lipases, glycosidases, and sulfatases [1].  Lysosomes are responsible 
for a variety of degradative processes. They degrade phagocyte-engulfed particles and 
microorganisms (endocytosis and phagocytosis), cellular organelles that have exceeded 
their lifespan and become obsolete (autophagy), and targeted proteins that contain a 
selective signaling motif (often KFERQ) on their surface [1].   
The lysosome is defined as “the terminal organelle of the endocytic pathway and 
one that is devoid of recycling receptors [28, 29]”.  Substrates are acquired for endocytic 
degradation via complex signaling networks mediated by PI-3 kinase and small G-protein 
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cascades as well as by actin [28].  Proteins are first endocytosed into early “sorting” 
endosomes, where they are either shuttled back to the plasma membrane for recycling 
(e.g. receptor-ligand complexes) or are transferred into endosome carrier vehicles (ECVs) 
that transport the protein to the late endosomes.  From the late endosomes, proteins are 
carried to the lysosomes, where a fusion of the endosomal/lysosomal compartments 
mediates delivery of the protein substrate to the hydrolytic enzymes [30].  Figure 1.6 
outlines the stages of the endocytic pathway.  At each stage, the pH of the organelles 
drops considerably, culminating in a pH of about 5 in the lysosomal compartment.  
Acidification is important for optimal activity of lysosomal membrane transporters.  
Additionally, most lyosomal hydrolases are activated (often by autoactivation) and 
exhibit optimal activity at acidic pH [28].  
Newly synthesized lysosomal enzymes are sequestered in the lysosomal 
compartment via unique mannose 6-phosphate (M6P) groups that attach to the termini of 
N-linked oligosaccharides [1].  The lysosomal hydrolases are heavily glycosylated 
tructures that are recognized by the M6P receptor proteins, which bind and direct  spackaging of lysosomal enzymes into clathrin-coated transport vehicles that deliver them 
to the late endosomes/lysosomes [31, 32].  In this manner, the acid hydrolases of the 
lysosomes are sequestered from the rest of the cell. 
Because hydrolytic enzymes could trigger massive cellular destruction in the 
cytosol, lysosomes must be tightly regulated to control the influx and efflux of proteins.  
All lysosomal enzymes exhibit maximal activity at an acidic pH, which the lysosomal 
compartment provides by utilizing an ATP-driven H+ pump to maintain interior 
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Figure  1.6.  Stages of the endocytic pathway.  Endocytosed particles are first 
taken to the ‘sorting’ endosome, where they may be recycled or passed on to the 
endosomal carrier vehicle (ECV).  The ECV shuttles the cargo to the late 
endosome, which then fuses with the lysosome for delivery to the hydrolytic 
enzymes.  The color change in compartments (purple-red-orange-yellow) 
represents a decrease in pH with progression to each vesicle. 
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acidification [33].  As a precaution against lysosomal enzymes causing fortuitous damage 
to the cell, the lysosomal membrane is specifically designed to tightly guard against 
accidental leakage of hydrolytic enzymes.  Almost all lysosomal membrane proteins are 
extensively glycosylated, which not only protects them against the digestive properties of 
the acidic interior, but also serves to mediate transport across the membrane [34, 35].  In 
order to pass across these heavily glyscosylated membranes, proteins must possess 
distinct recognition signals that target them for internalization.  The membrane acts in the 
same way to prevent release of hydrolases from the compartment.  As an additional 
safeguard against accidental cellular digestion, many of the lysosomal enzymes are 
completely or nearly inactivated at neutral pH; therefore, if they are inadvertently 
released into the cytosol, most can do little damage to the cell [1].  An exception to this 
rule is the cysteine protease family, of which several members are highly active at neutral 
pH, posing a potential hazard to the cell if relocalized.  As a prime example of how 
dangerous lysosomal protease activation outside of the compartment can be, secreted 
cysteine cathepsins have been implicated in cancer progression by degrading the 
extracellular matrix around malignant cells, allowing tumor cell dissemination from the 
primary tumor [36].  Therefore, regulation of the localization of lysosomal proteases is 
critical for normal cellular function. 
As mentioned previously, there are several types of hydrolytic enzymes present in 
the lysosomes.  Proteins that have been targeted to the lysosomes for degradation are 
digested by peptidases, also known as proteinases or proteases [37, 38].  Though 
lysosomal proteases represent only a small fraction of the total cellular protein, the 
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cathepsin proteases account for up to 40% of the lysosomal hydrolytic enzyme content in 
the cell.   
 
1.5. THE  CATHEPSIN  FAMILY 
As with all proteases, the 15 members of the cathepsin family are characterized 
according to their catalytic site.  In addition to their role in digestion of unessential 
cellular material, the cathepsins represent a family of proteases with extraordinarily 
diverse functions.  The 11 cysteine cathepsins (B, C, F, L, K, V, S, X/Z, H, W, and O) are 
by far the largest cathepsin subfamily and are the most well-characterized [36].   
Cathepsin B plays a role in migration of cells following wound healing and in the 
inflammatory response [39].  Cathepsin L functions in secretory vesicles to process pro-
hormones for production of the neurotransmitter enkephalin [40]. 
The serine cathepsins (A and G) are less well-characterized.  Cathepsin A 
possesses a function that is independent from its enzymatic activity.  In addition to its 
role in proteolytic degradation, procathepsin A acts as a protection protein by binding and 
stabilizing β-galactosidase in the lysosomes [41].  Cathepsin G cleaves and inactivates 
proteins involved in blood clotting, plays a role in neutrophil response to a variety of 
bacteria, and also is important in tissue remodeling during wound healing [42].    
While the aspartate cathepsins (D and E) share considerable homology in their 
amino acid sequences, their cellular function and localization is very different.  Cathepsin 
E is necessary for the MHC Class I antigen processing pathway in dendritic cells. 
However, its mechanism of action is unknown [43, 44].  Unlike the other cathepsins, 
cathepsin E is not localized exclusively to the lysosomal compartment;  localization and 
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expression of cathepsin E differs between cell types [45].  Cathepsin D, which is 
localized solely in the lysosomal/endosomal compartments in normal cells, has been 
implicated in inflammatory processes and tumor invasion, and is vital for development of 
the intestinal mucosa and lymphoid cells [46].  As cathepsin D is the focus of my study, it 
will be discussed in detail. 
Figure 1.7 contains a current list of the cathepsin proteases.  Despite their varying 
functions, cathepsin proteases share one common feature: they degrade proteins that have 
been targeted for destruction via the endocytic pathway.  Because these enzymes are 
usually completely sequestered within the lysosomal compartment, the concept of an 
extra-lysosomal role was given little credence.  Recent evidence, however, has shed light 
on roles for several members of the cathepsin family in the apoptotic process.   
 
1.5.1. CATHEPSINS  IN  APOPTOSIS 
Lysomotropic agents are lipophilic bases that induce lysosomal destabilization by 
accumulating in the lysosomal lumen, disrupting the membrane in a manner similar to 
detergents.  Firestone et al. [47-49] demonstrated that selective lysomotropic rupture of 
the lysosomal compartment induced cell death.  Their description of the morphological 
changes in the dying cells could be categorized as classic apoptosis.  More recently, 
studies have shown that addition of lysomotropic agents such as the antibiotics 
norfloxacin and ciprofloxacin induce apoptosis in HeLa cells via activation of the 
proapoptotic mitochondrial proteins Bax and Bak [50, 51].  Additionally, the detergents 
sphingosine and O-methyl-serine dodecylamide hydrochloride (MSDH) induce 
lysosomal rupture and subsequent apoptosis in Jurkat leukemic and J774 macrophage-
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 Cathepsin Type Inhibitors 
Cathepsin A Serine Boc-VF-NHO-Bz-pCl 
Cathepsin B Cysteine Leupeptin, Ac-LVK, z-FG 
Cathepsin C Cysteine N/A 
Cathepsin D Aspartate Pepstatin A 
Cathepsin E Aspartate Pepstatin A 
Cathepsin F Cysteine N/A 
Cathepsin G Serine Boc-VF-NHO-Bz-pCl 
Cathepsin H Cysteine Stefins 
Cathepsin K Cysteine 1,3-Bis(N-carbobenzoyloxy-L-leucyl)amino Acetone 1,3-Bis(CBZ-Leu-NH)-2-propanone 
Cathepsin L Cysteine z-FF, z-FG 
Cathepsin O Cysteine N/A 
Cathepsin S Cysteine z-FG, z-FL 
Cathepsin V Cysteine N/A 
Cathepspin W Cysteine N/A 
Cathepsin X/Z Cysteine N/A 
 
 
Figure  1.7.  Cathepsin Proteases 
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like cells, as well as in HeLa epithelial cells and AG1518 fibroblasts [51, 52]. 
Even with this evidence, however, many assumed the role of lysosomes was 
restricted to an autophagic role (type II programmed cell death) in the late stages of cell 
death.  Autophagy is characterized by morphological changes that differ from apoptosis 
(type I programmed cell death).  During apoptosis, cytoplasm and chromatin condense, 
inducing cell shrinkage.  During autophagy, cytoplasmic constituents are fragmented and 
distinct autophagic vacuoles are formed [53].  Additionally, apoptotic cells fragment into 
small apoptotic bodies, while an autophagic cell stays intact throughout the cell death 
process [54].  Both type I and type II programmed cell death are completed by lysosomal 
degradation of cellular constituents [54].  Dying cells can undergo both type I and II 
programmed cell death simultaneously; therefore, it is possible that the role of lysosomes 
is not mutually exclusive to one type of cell death [55].    
Recent evidence points to a distinct role for lysosomal proteases in apoptosis.  
Several lysosomal storage disorders arise as a result of a lack or accumulation of 
lysosomal enzymes [56].  Interestingly, many of these diseases are characterized by either 
an inhibition or an exacerbation of cell death, suggesting that lysosomal enzymes may be 
important for the apoptotic process [56].  Stoka et al. [57] demonstrated that while the 
cathepsin proteases did not directly cleave caspase proteases, lysosomal extracts induced 
the cleavage of the proapoptotic factor Bid to its active form.  Cleaved Bid is capable of 
promoting cytochrome c release and subsequent activation of caspases.  Incubation of 
mitochondria with Bid that had been cleaved by lysosomal extracts in vitro was found to 
induce cytochrome c release, suggesting that cathepsins might play a role in caspase 
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activation by acting through Bid.  The effects on Bid by the cathepsins, especially 
cathepsin D, will be discussed in Chapter 5.   
In vivo assays have also demonstrated that lysosomal proteases are important for 
apoptosis.  Yuan et al. [58] developed a M1-t-p53 myeloid cell line with a temperature-
sensitive p53 protein that was active at 32 °C.  Using these cells, they showed that p53-
induced apoptosis was initiated by lysosomal destabilization and release of lysosomal 
contents.  Also, Zang et al. [59] showed that labeling of lysosomes in HL-60 cells using 
the synthetic retinoid CD437 induced leakage of lysosomal contents.  The cathepsin D 
inhibitor pepstatin A prevented formation of free radicals and apoptosis following 
treatment with CD437, suggesting a direct role for the cathepsins in CD437-induced 
apoptosis.  Reports have also revealed a role for lysosomal proteases in apoptosis induced 
by supraoptimal activation of T lymphocytes [60], Hsp70 depletion [61], and 
photodamage [62].  Taken together, these studies suggest that lysosomal enzymes may 
play an active role in various types of apoptosis. 
   
1.5.2. CATHEPSIN B  AND  CATHEPSIN L  IN  APOPTOSIS 
Of all the lysosomal enzymes, the cysteine cathepsins (specifically cathepsin B) are 
the most well-characterized.  Cathepsin B is synthesized as a 38 kD zymogen that is 
ubiquitously expressed in high levels [63].  Proteolytic cleavage generates a 31 kD 
mature form, followed by subsequent processing to 27 kD and 5 kD fragments that are 
linked via interchain disulfide bonds [64].  In addition to its role in proteolytic 
degradation, cathepsin B has been implicated in extracellular matrix remodeling [65].   
Cathepsin B can be secreted, where it promotes tumor migration and invasion by 
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degrading extracellular matrix proteins such as collagen, laminin, and proteoglycans [66].  
Additionally, studies have shown that several apoptotic stimuli evoke relocalization of 
cathepsin B to the cytoplasm during cell death.  For instance, the microtubule-stabilizing 
agents (MSAs) paclitaxel, epothilone B, and discodermolide all induce relocalization of 
cathepsin B to the cytosol, accompanied by activation of the enzyme [67].  Additionally, 
this study demonstrated that inhibition of cathepsin B with CA-074 Me and zFA-FMK 
protected H460 lung cancer cells from death induced by the aforementioned drugs. 
Several reports have shown that cathepsin B is also important in cell death induced 
by the death receptor ligand TNF-α.  Antisense-mediated downregulation of cathepsin B 
in WEHI-S leukemic cells, as well as treatment with the cathepsin B inhibitors CA-074-
Me and zFA-FMK, significantly protected against cell death induced by either TNF-α or 
TRAIL [68].  TNF-α-induced cytochrome c release, caspase activation, and apoptosis 
were markedly diminished in cathepsin B-/- mice following stimulus with TNF-α [64, 
69].  In line with this, cathepsin B was relocalized from the lysosomes to the cytosol 
following TNF-α treatment [64, 68, 70, 71].  The selective release of cathepsin B from 
lysosomes has also been noted for bile salt-induced apoptosis [69], TNF-α-mediated 
hepatocyte apoptosis [69, 72], and supraoptimal activation of T lymphocytes [60].  
Evidence suggests that the release of cathepsin B into the cytosol is caspase dependent 
[64, 68].  Interestingly, forced overexpression of cathepsin B, resulting in protein 
expression levels similar to those found in tumors, did not sensitize the cells to TNF-α-
mediated apoptosis, suggesting that the basal levels of cathepsin B are sufficient to 
initiate the stimulus for apoptotic signaling [73]. 
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Cathepsin B initiates an apoptotic cascade following treatment with TNF-α and bile 
salts or after supraoptimal activation of T lymphocytes, resulting in the downstream 
activation of the executioner caspases.  The mechanism of cathepsin B-induced apoptosis 
remains unknown.  However, it is understood that while cathepsin B can directly activate 
the inflammatory caspases, caspase-1 and caspase-11, it cannot directly activate 
proapoptotic caspases [57, 74].  This evidence suggests that cathepsin B likely acts on an 
intermediary factor to induce caspase activation. 
Preliminary studies suggest that the cysteine protease cathepsin L may also be 
involved in apoptotic events.  Cathepsin L, like cathepsin B, can be secreted in response 
to growth factors, transformation, and tumor promoters [75].  Cathepsin L and cathepsin 
B are also important in neurological development, as deficiencies of the two proteases are 
lethal early in life [65].  While a definitive proapoptotic role of cathepsin L has not been 
elucidated, some studies have shown that activation of caspase-3 is enhanced in vitro by 
cathepsin L, implying that cathepsin L may be involved in the process of caspase-3 
activation [76, 77].   
 
1.6. CATHEPSIN D 
Cysteine cathepsins are not the only potential mediators of apoptosis present in the 
lysosomes.  Over the past 10 years, evidence has implicated a role for the aspartate 
protease cathepsin D in apoptosis induced by several types of stimuli.  The section that 
follows outlines the current knowledge of cathepsin D and its role in normal cells as well 
as in apoptotic cells. 
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1.6.1. STRUCTURE  AND  EXPRESSION 
Cathepsin D, like all lysosomal proteases, undergoes a variety of processing steps during 
its synthesis and maturation.  It is made as a preproenzyme that is targeted to the 
endoplasmic reticulum (ER) via a 20 amino acid N-terminal signal peptide sequence.  
This sequence interacts with a signal recognition particle that induces receptor-mediated 
transport of cathepsin D across the endosomal membrane [78].  Because this prepeptide 
sequence is removed cotranslationally by a luminal signal peptidase, the cathepsin D 
preproenzyme is never detected in cells [37, 38].  Similar to other cathepsins, a 44-
residue prodomain keeps procathepsin D inactive during transport and is removed 
sometime before final transport to the mature lysosomes.  Following cleavage of the 
prodomain, a single-chain active form of cathepsin D is generated.  Further processing 
results in an active light-chain/heavy-chain form of the enzyme in human tissues.  Late in 
the biosynthesis process, cathepsin D also undergoes proteolytic “trimming”, during 
which it loses another seven amino acids between the heavy and light chains as well as 
two amino acids at the carboxy terminus.  As this processing occurs following a 
significant pH drop in the vesicle (a step that often accompanies fusion of a lysosome 
with a phagosome), it is believed that it occurs as a final enzymatic activation step [37].  
Figure 1.8 depicts the structure of the cathepsin D protein and cleavage/activation sites. 
The cathepsin D protein also acquires a high-mannose oligosaccharide chain on 
each chain during translation [38].  Phosphorylation of these chains occurs in the early 
Golgi by a lysosome-specific phosphotransferase enzyme, N-acetylglucosamine 1-
phosphate [79].  The removal of the N-acetylglucosamine then exposes the phosphate as a
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Figure  1.8. Structure of cathepsin D.  The cathepsin D protein is comprised of a 
predomain, a prodomain, a 15 kD light chain, and a 34 kD heavy chain.  During the 
course of biosynthesis and activation, proteolytic processing cleaves the single chain 
preprocathepsin D enzyme to an active double chain form.  Additional proteolytic 
processing of 7 amino acids between the heavy and light chains and 2 amino acids at the 
carboxyl terminus are needed for full activation of the enzyme.  Arrows depict processing 
sites.  See text for details on the function of each domain. 
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recognition signal for binding to mannose-6-phosphate (M6P) receptors in the late Golgi, 
which targets the enzyme to the late endosomes.   
Cathepsin D that is localized in the lysosomes associates with the membrane via a 
M6P-independent mechanism.  Though the significance of this membrane interaction is 
unclear, it has been shown that while procathepsin D is membrane-bound, active enzyme 
is soluble [80].  Therefore, membrane dissociation may be associated with activation of 
the protease [81]. 
It is clear that sequestration of lysosomal hydrolases is vital for safeguarding the 
cell from self-digestion.  A variety of precautionary measures target and maintain 
cathepsin D within lysosomes, including specific signaling peptides, M6P-receptor 
targeting, and cathepsin D-membrane association [38].  Despite these safeguards, 
transformed cells such as MCF-7 breast cancer cells have the ability to dissociate 
cathepsin D from the membrane in a M6P-independent manner [38, 82].  In these cells, 
cathepsin D is secreted as a proenzyme, where it can degrade intact basement membranes 
and contribute to the metastatic potential of tumors [83, 84].  Evidence also suggests that 
secretion of procathepsin D enhances cell proliferation in some types of ovarian tumors 
[85].  These data suggest that the secreted proform of cathepsin D can be quite 
detrimental in several types of cancers.   
Cathepsin D is necessary for normal tissue homeostasis [46].  Cathepsin D-/- mice 
are not impaired in their ability to undergo lysosomal bulk proteolysis, as cysteine 
proteases can elicit a compensatory mechanism for this loss.  However, although they 
develop normally for about two weeks, CD-/- mice soon exhibit intestinal atrophy and a 
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significant decrease in the number of T and B lymphocytes of the spleen and thymus.  
Therefore, cathepsin D is essential both in the development of adult epithelial cells of the 
gut as well as the development of T and B lymphocytes in central and peripheral 
lymphoid organs [46].   
Cathepsin D is expressed in high levels in all cell types and accounts for as much as 
11% of the total lysosomal enzyme content [78].  Cathepsin D, which is a member of the 
pepsin proteinase family, is a bilobed molecule that is primarily comprised of β-sheets 
and contains a deep active site cleft in which Asp-215, Asp-32, and Serine-35 are critical 
residues [46, 86].  Cathepsin D prefers to cleave substrates between dipeptide bonds 
(usually Phe-Phe) that are flanked by bulky hydrophobic amino acids at a pH optimum 
between 2.8 and 4 [87].  As I will show, cathepsin D maintains enzymatic activity up to a 
pH of 7.0.       
 
1.6.2. CATHEPSIN D  IN  APOPTOSIS 
The possibility that lysosomal cathepsin D plays an important role in the cell death 
pathway has come as a surprise to the apoptosis research community.  In 1996, Deiss et 
al. [88] were attempting to isolate positive mediators of interferon (IFN)-γ-induced cell 
death utilizing a strategy in which random genes were inactivated following transfection 
with antisense cDNA expression libraries.  The clones containing cDNA inserts that 
protected against IFN-γ-induced cell death were rescued and sequenced for identification.  
One of the isolated cDNAs was found to correspond to a fragment of human cathepsin D 
cDNA.  In the same study, cathepsin D antisense RNA and the cathepsin D inhibitor 
pepstatin A were shown to protect HeLa cells from Fas/APO-1-, TNF-α,- and IFN-γ-
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mediated cell death.  Another study showed that pepstatin A elicited protection from 
TNF-α-induced cell death in L929 fibroblasts [89].   
Apoptosis can also be induced by the quinone naphthazarin through production of 
superoxide radicals [90, 91].  In a series of studies, Roberg et al. [90-92] demonstrated 
through immunohistochemical methods that cathepsin D was relocalized to the cytosol 
following a short exposure to oxidative stress.  It was postulated that the production of 
hydroxyl radicals destabilized the lysosomal membranes through lipid peroxidation and 
provoked a generalized leakage of the lysosomal contents into the cytosol.  Pepstatin A 
also prevented oxidative stress-induced cytochrome c release and loss of mitochondrial 
membrane potential (∆Ψm) in cardiomyocytes [90, 92].  Additionally, oxidative stress-
mediated caspase activation was inhibited in cardiomyocytes that were pretreated with 
pepstatin A [93].  It is important to note, however, that although pepstatin A did protect 
against oxidative stress-induced apoptosis, it did not prevent cytoplasmic relocalization 
of cathepsin D [93].  These results suggest that cathepsin D acts as an upstream factor 
that regulates cytochrome c release and subsequent caspase activation following 
oxidative stress. In support of this, Roberg et al. [94] demonstrated that microinjection of 
cathepsin D into human fibroblasts induced apoptosis via cytochrome c release and 
caspase activation.  Similarly, pepstatin A protected alveolar epithelial cells against 
apoptosis induced by the fibrogenic agent bleomycin [95].   
Research has also suggested that cathepsin D may be important in ceramide-induced 
apoptosis.  Ceramide is an intracellular signaling molecule that transduces the effects of 
exogenous stimuli such as growth factors or cytokines for cellular functions such as 
proliferation or apoptosis [96, 97].  Ceramide acts as a mediator in the apoptotic process 
 29
induced by cytotoxic cytokines.  Although a definitive role for cathepsin D in ceramide-
mediated apoptosis has not been established, it has been demonstrated that ceramide 
binds to procathepsin D, resulting in autocatalytic proteolysis of cathepsin D to its active 
double-chain form [96].   
Additionally, a role for cathepsin D has been suggested for apoptosis caused by the 
broad-spectrum protein kinase inhibitor staurosporine.  Treatment of human foreskin 
fibroblasts with pepstatin A inhibited staurosporine-induced cytochrome c release, 
caspase activation, and apoptosis [98]. Following staurosporine treatment of T 
lymphocytes, cathepsin D triggered Bax activation followed by subsequent release of the 
mitochondrial apoptogenic protein AIF-1 [99, 100].  AIF-1 contributes to apoptosis in a 
caspase-independent manner.  The fact that cathepsin D may play a proapoptotic role in 
both a caspase-dependent and a caspase-independent pathway suggests that cathepsin D 
may participate in more than one signaling cascade that culminates in apoptosis or that its 
mechanism of action during apoptosis may be cell- or stimulus-dependent. 
In 1998, a study by Wu et al. [101] showed that cathepsin D protein expression 
increased following etoposide treatment in ML1 cells.  This same study demonstrated 
that cathepsin D-deficient fibroblasts were partially protected against etoposide-induced 
cell death.  Though these data suggest that cathepsin D might also mediate 
chemotherapy-induced apoptosis, the role of cathepsin D in the chemotherapy-induced 
apoptotic pathway has remained largely unexplored. 
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1.7. STATEMENT  OF  PROBLEM  AND  HYPOTHESIS 
The apoptotic cascade represents a complex process that culminates in the 
destruction and degradation of the cell.  One characteristic of many cancer cells is their 
ability to evade apoptosis, thus maintaining an immortal status.  Many mediators of the 
apoptotic cascade have been well characterized.  However, as the incidence of 
chemotherapeutic drug-resistance rises, the discovery and characterization of novel 
apoptosis regulatory proteins that have potential to become drug targets is vital.  
Lysosomal proteases, particularly the aspartate protease cathepsin D, have been 
implicated in apoptosis induced by a variety of stimuli, including death receptor ligands, 
oxidative stress, and protein kinase C inhibitors.  Very little is known about the role of 
cathepsin D in chemotherapy-induced apoptosis, but preliminary evidence suggests that it 
may be a potential apoptotic mediator of chemotherapy drugs as well.  The hypothesis of 
this project is that cathepsin D is important for chemotherapy-induced apoptosis.  
Because it would be difficult for a sequestered lysosomal enzyme to directly mediate 
apoptosis signal transduction, these studies will first examine the subcellular localization 
of cathepsin D following chemotherapy-treatment.  This project will also examine the 
impact of siRNA-mediated cathepsin D downregulation on chemotherapy-induced 
apoptosis in two different cell lines.  Finally, this project will attempt to shed light on the 
molecular mechanism of cathepsin D action in the chemotherapy-induced apoptotic 
pathway. 
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2. MATERIALS  AND  METHODS 
2.1.        MATERIALS 
Polyclonal antibodies to cathepsin D and cathepsin B, hygromycin B, and the 
caspase inhibitor z-VAD-FMK were purchased from Calbiochem (San Diego, CA).  
Caspase-8 inhibitor (z-IETD-FMK), cathepsin B inhibitor (z-FA-FMK) and cathepsin L 
inhibitor (z-FF-FMK) also were from Calbiochem.  Pepstatin A was obtained from Roche 
Applied Sciences (Indianapolis, IN).  Polyclonal anti-caspase-3 antibody and monoclonal 
anti-caspase-8 antibody were purchased from Cell Signaling Technology (Beverly, MA).  
Polyclonal anti-cathepsin E antibody was purchased from Santa Cruz (Santa Cruz, CA). 
Monoclonal anti-cytochrome c oxidase IV antibody was obtained from Molecular Probes 
(Eugene, OR). Polyclonal anti-Smac antibody was purchased from R&D Systems 
(Minneapolis, MN).  Monoclonal β-actin antibody, VP-16, cisplatin, 5-fluorouracil, 
cycloheximide, naphthazarin, and DMSO were from Sigma (St. Louis, MO).  
Staurosporine was purchased from Upstate Biotechnology (Lake Placid, NY).  
Sphingosine was obtained from EMD Biosciences (San Diego, CA).  Monoclonal 
cytochrome c antibody and the caspase-3 substrate Ac-DEVD-AFC were obtained from 
BD Pharmingen (San Diego, CA).  The cathepsin D substrate MoCAc-Gly-Lys-Pro-Ile-
Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2 was purchased from Peptides International 
(Louisville, KY).  The β-hexosaminidase substrate, 4-methylumberriferyl-N-acetyl-β-D-
glucosaminide dehydrate, was purchased from Sigma.  TRAIL and TNF-α were from 
PeproTech, Inc (Rocky Hill, NJ).   
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2.2. CELL  CULTURE 
Wild-type U937 cells were cultured in RPMI media (BioWhittaker) containing 
10% fetal bovine serum, 100 µg/ml penicillin-streptomycin, and 0.5 µg/ml amphotericin 
B (fungizone).  U937 clones transfected with siRNA constructs were supplemented with 
250 µM hygromycin B (Calbiochem) with every media change.  Wild-type HeLa cells 
were cultured in DMEM media (Mediatech) containing 10% fetal bovine serum, 100 
µg/ml penicillin-streptomycin, and 0.5 µg/ml amphotericin B.  HeLa clones containing 
cathepsin D siRNA were supplemented with 250 µM hygromycin B.  All cells were 
maintained at 37 °C in the presence of 5 % CO2. 
 
2.3. INDUCTION  OF  CELL  DEATH 
One day prior to drug treatment, HeLa cells were plated in 24 well plates at a 
density of 3 x 105 cells/ml.  Wells were washed with PBS before addition of the drug-
containing media.  For drug treatment in U937 cells, cells were harvested by 
centrifugation at 1,300 rpm for 5 minutes at 4 °C.  Following a wash with PBS, U937 
cells were resuspended in RPMI media to a concentration of 8 X 105 cells/ml.  To induce 
U937 cell death, cells were incubated at 37 °C with the following drugs: 2 µM VP-16,     
2 µg/ml TRAIL, 1 µM staurosporine, or 1 µM napthazarin.  For TNF-α-induced 
apoptosis, U937 cells were treated simultaneously with 10 ng/ml TNF-α and 10 µg/ml 
cycloheximide.  To induce apoptosis in HeLa cells, cells were incubated at 37 °C with the 
following drugs: 100 µM VP-16, 5 µM 5-fluorouracil, 10 µM cisplatin, 1 µM 
staurosporine, 1 µM napthazarin, or 10 µM sphingosine.  HeLa cells were also treated 
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with 10 ng/ml TNF-α and 10 µg/ml cycloheximide concomitantly.  Drugs were utilized 
at a 1:1000 dilution in media. All drug stock solutions were dissolved in DMSO; 
therefore, control samples in experiments were treated with 0.1% DMSO.  Untreated 
HeLa and U937 cells always exhibited greater than 97% viability throughout experiments 
involving cell death.  At the designated time points, aliquots of cells were taken for 
viability analysis.  In the case of HeLa cells, media was removed from the wells and the 
wells were washed with PBS.  The wells were then treated with 200 µl trypsin/EDTA for 
a sufficient length of time to release the cells from the plate (about 1 minute).  The 
cellular mixtures of media, PBS, and trypsin were centrifuged at 2,000 rpm for 4 minutes 
at room temperature, and the pellets were resuspended in 100 µl PBS.  Cell viabilities 
were assessed by adding an equal volume of trypan blue exclusion dye and counting a 
minimum of 100 cells to assess dye uptake.  In the viability counts, the ratio of clear 
translucent cells (excluding dye) to total cells indicated the percentage of viable cells; 
clear cells represented viable cells and blue cells represented dead or dying cells.  All 
counts were done in triplicate; error bars represent standard deviations. 
 
2.4. CYTOSOLIC  ISOLATION  AND  CATHEPSIN D  RELOCALIZATION 
To assess subcellular relocalization of cathepsin D following chemotherapy 
treatment in wild-type U937 cells, 20 X 106 U937 cells treated with either DMSO, TNF-
α  + cycloheximide, staurosporine, or VP-16 were harvested by centrifugation at 1,300 
rpm for 5 minutes at 4 °C, followed by 2 washes with ice-cold PBS.  The cell pellets 
were resuspended in 400 µl resuspension buffer (20 mM HEPES, pH 7.4, 10 mM KCl, 
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1.5 mM MgCl2, 1 mM EDTA, 250 mM sucrose, 1 mM DTT, 1.5 mM PMSF, 3 µg/ml 
leupeptin, and 20 µg/ml aprotinin) and homogenized on ice by 20 strokes with a Wheaton 
Type B Dounce homogenizer (Kontes Glass, Vineland NJ).  Cell homogenates were 
centrifuged at 14,000 rpm for 30 minutes at 4 °C.  The supernatants, which contained the 
cytosolic fraction, were then subjected to another 30 minute centrifugation for further 
clarification.  The pellets, which consisted of a crude heavy-membrane fraction that 
contained isolated lysosomes, were purified further by two washes in resuspension buffer 
and microcentrifugation at 14,000 rpm for 10 minutes at 4 °C.  Bio-Rad protein assay dye 
reagent (Bio-Rad Labs, Hercules, CA) was used to determine protein concentrations in 
both the pellet and supernatant fractions.  25 µg/lane of protein was used for 
immunoblotting with anti-cathepsin D. 
 
2.5. ISOLATION OF MITOCHONDRIA 
To isolate mitochondria from wild-type U937 cells, 20 X 106 cells were 
centrifuged at 1,300 rpm for 5 minutes at 4 °C, washed with PBS, and centrifuged again.  
The cell pellets were resuspended in 400 µl resuspension buffer (20 mM HEPES, pH 7.4, 
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 250 mM sucrose, 1 mM DTT, 1.5 mM 
PMSF, 3 µg/ml leupeptin, and 20 µg/ml aprotinin) and subjected to 20 strokes in a Type 
B Dounce homogenizer.  The homogenates were then centrifuged for 30 minutes at 
14,000 rpm at 4 °C.  The enriched mitochondrial pellets were washed twice with cold 
resuspension buffer, then resuspended in 100 µl of resuspension buffer.  The 
supernatants, containing cytosolic proteins, were further clarified by two rounds of 
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centrifugation at 14,000 rpm for 30 minutes at 4 °C.  Protein concentrations were 
estimated using Bio-Rad protein dye reagent; 50 µg of mitochondrial protein and 10 µg 
of cytosolic protein were used for cell-free cytochrome c-release assays. 
 
2.6. CATHEPSIN D  siRNA  CONSTRUCTION  AND  LIGATION  INTO    
            pSILENCER VECTOR 
siRNA sequences suitable for targeting of cathepsin D mRNA were identified 
using the Ambion siRNA target finder (www.ambion.com).  Five oligonucleotides were 
designed, containing appropriate 21-nucleotide sense and antisense sequences separated 
by a hairpin loop, according to Ambion recommendations (See chapter 4 for specific 
details).  Oligonucleotides were synthesized by Integrated DNA Technologies, Inc.  
Oligonucleotides contained Hind III and Bam HI restriction sites at their 5’ and 3’ ends, 
respectively.  Single-stranded oligonucleotides were annealed by combining 1 µg/µl of 
homologous oligonucleotides, denaturing for 3 minutes at 90 °C, and annealing for 1 
hour at 37 °C.   The annealed oligonucleotides were cleaved by Hind III and Bam HI 
restriction enzymes, then ligated into the corresponding sites of the Ambion pSilencer 
2.1-U6 hygro vector by incubating oligonucleotides with vector (1 part oligonucleotide to 
40 parts vector) for 3 hours at room temperature in the presence of 5 units of T4 DNA 
ligase.   
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2.7. TRANSFORMATION  AND  CONSTRUCT  PREPARATION 
For each siRNA target sequence, 40 ng DNA from pSilencer vector containing an 
siRNA sequence was incubated with competent DH5-α bacteria for 40 minutes at 4 °C.  
Samples were heat-shocked for 2 minutes at 42 °C, then incubated at room temperature 
for 5 minutes.  The bacteria were then incubated with LB media for 1 hour and plated 
onto LB plates containing 50 mg/ml ampicillin for incubation overnight at 37 °C.  
Plasmid DNA was purified from bacterial colonies (Promega WizardPLUS minipreps), 
and DNA sequencing was used to verify that the siRNA sequences were correctly 
incorporated into the pSilencer vector. 
  
2.8. TRANSFECTION  OF  pSILENCER  CONSTRUCTS INTO  U937  AND   
            HELA  CELLS 
Plasmid DNAs were transfected into HeLa and U937 cells using the 
GenePORTER 2 Transfection reagent (Gene Therapy Systems).  DNAs (4 µg/sample) 
were transfected into cells at a density of 2 x 106 cells/ml in a 6-well plate under serum-
free conditions.  Fresh growth media containing 20% serum was added 3 hours post-
transfection.  Hygromycin B was added to a concentration of 250 µM after 48 hours.  
Cells were maintained for 3 weeks in hygromycin B-containing media, with media being 
replenished every 3 days.  Surviving clones were isolated by limiting dilution (U937) or 
cloning cylinders (HeLa) and expanded in media containing hygromycin B.  The 
sequence that was complementary to the cathepsin D gene at nucleotide 144 (5’-
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AGGCCCCGUCUCAAAGUACUU -3’) proved the most effective at silencing cathepsin 
D in both HeLa and U937 cells (See Chapter 4).  
 
2.9. IMMUNOBLOTTING 
Following SDS-PAGE electrophoresis on 16 cm gels, the gels were transferred to 
nitrocellulose membrane at 45 V for 3 hours.  For mini-gels, gel transfer to nitrocellulose 
was done at 100 V for 1 hour.  Membranes were blocked in 5% dry milk/TBST (50 mM 
Tris, pH 8.0, 0.15 M NaCl, 0.1% Tween-20) for 1 hour, followed by a quick rinse in 
TBST.  Primary antibodies were diluted in TBST containing 1% bovine serum albumin 
and incubated overnight at 4 °C with the membrane.  Antibody dilutions are listed in 
Appendix B.  Following incubation with primary antibody, the membranes were washed 
for 15 minutes with TBST, followed by three washes of 5 minutes each.  Secondary 
antibody, diluted 1:4000 in TBST containing 1% milk, was then added to the membrane 
for 1 hour at room temperature.  Secondary antibody for β−actin was used at a 1:5000 
dilution.  Following incubation with secondary antibody, the membranes were washed for 
15 minutes in TBST, followed by three 5 minute washes.  Membranes were then dried 
and developed using the Western Lightning Renaissance ECL reagent.   
 
2.10. PREPARATION  OF  WHOLE  CELL  EXTRACTS 
To prepare whole cell extracts for enzymatic cleavage assays or for 
immunoblotting, 5 X 106 cells were subjected to centrifugation at 4 °C for 5 minutes at 
1,300 rpm, followed by a wash with PBS.  Cell pellets were resuspended in 75 µl lysis 
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buffer (50 mM Tris, pH 8, 5 mM EDTA, 150 mM NaCl, 0.5% NP-40), incubated on ice 
for 10 minutes, then centrifuged at 4 °C for 10 minutes at 14,000 rpm.  The protein 
concentration of the supernatant was quantified using Bio-Rad Protein Dye Reagent.     
25 µg of protein per lane was used for immunoblotting, and 20 µg of protein per sample 
was used for enzymatic cleavage assays. 
 
2.11.  CHEMOTHERAPY-INDUCED  CYTOCHROME C  RELEASE   
 ASSAYS 
For investigation of cytochrome c release in chemotherapy-treated U937 cells,   
20 X 106 cells were treated with 2 µM VP-16 or an equivalent amount of DMSO (0.1%) 
over a time course of 24 hours.  At designated time points, cells were harvested by 
centrifugation at 1,300 rpm for 5 minutes at 4 °C, followed by a wash in cold PBS.  
Cytosolic fractions were isolated and quantified as described in Section 2.4.  Cytosolic 
proteins (25 µg/lane) were electrophoresed on 13% SDS-PAGE gels, transferred to 
nitrocellulose membranes, and immunoblotted for cytochrome c.  To assess release of 
cytochrome c from isolated mitochondria in cell-free assays, mitochondria were isolated 
from untreated wild-type U937 cells as described in Section 2.5.  Proteins (50 µg/sample) 
from the mitochondria-containing pellets were incubated with 2 µg cathepsin D in the 
presence or absence of 10 µg of cytosolic extract in a total of 50 µl for 1 hour at 37 °C.  
Inhibitors were used at the following concentrations: 100 µM pepstatin A, 100 µM z-
VAD, 100 µM IETD, 100 µM Cathepsin B inhibitor, and 100 µM Cathepsin L inhibitor.  
Samples were centrifuged at 14,000 rpm for 30 minutes at 4 °C, and the supernatants 
 39
were subjected to further similar centrifugation for 30 minutes.  Supernatant proteins (15 
µl/lane) were electrophoresed on 13% SDS-PAGE gels and subjected to immunoblotting 
for cytochrome c.    
 
2.12.  ENZYMATIC  CLEAVAGE  ASSAYS 
For caspase-3 enzymatic assays, 20 µg of whole cell extracts were added to reaction 
buffer containing 20 mM HEPES, pH 7.5, 100 mM NaCl, 10% glycerol, 5 mM DTT,  
and 1 mM PMSF to achieve total reaction volumes of 100 µl.  Ac-DEVD-AFC substrate 
(1 µM) was then added and the reactions were incubated at 37 °C for 2 hours.  Cleavage 
of the substrate was measured at Exλ= 400 nm and Emλ=505 nm using an L55 
luminescence/fluorescence spectrometer (Perkin-Elmer).  To measure cathepsin D 
activity, 5 µg of cytosolic extracts (Fig 3.6) or 5 µg of whole cell extracts (Fig 4.5B) were 
incubated with fluorogenic cathepsin D substrate (MoCAc-Gly-Lys-Pro-Ile-Phe-Phe-
Arg-Leu-Lys(Dnp)-D-Arg-NH2) for 1 hour at 37 °C.  Cleavage of this substrate was 
analyzed by fluorescence spectroscopy at Exλ=328 nm and Emλ=393 nm.  Cytosolic 
extracts (20 µg) were analyzed for β-hexosaminidase activity by assessing cleavage of 
the fluorogenic substrate 4-methylumberriferyl-Ν-acetyl-β-D-glucosaminide dehydrate in 
reaction volumes of 200 µl of 100 µM NaAc, pH 4.0.  Cleavage of the substrate was 
measured at Exλ=364 nm and Emλ=488 nm.  Error bars represent the standard deviations 
of three independent assays. 
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3. CATHEPSIN D  UNDERGOES  RELOCALIZATION  TO  THE  
CYTOSOL  FOLLOWING  CHEMOTHERAPEUTIC  DRUG  TREATMENT 
3.1. INTRODUCTION 
Lysosomal proteolytic enzymes normally function within cells to degrade proteins 
that are targeted to the lysosomal compartment [1].  The pH of the lysosomal 
compartment is approximately 5.0, and proteases that reside there are often only active at 
low pH [1].  Maximal lysosomal enzyme activity at an acidic pH is a protective measure 
for cells; if these enzymes were to leak into the cytosol, they could digest the entire cell.  
However, because they are not typically active at cytosolic pH (~7.2), if accidental 
leakage occurs, the presence of lysosomal proteases in the cytosol usually does little 
damage [1].   
Most apoptosis regulatory proteins reside within the cytosol or the mitochondria; 
therefore, the complex execution processes of cell death also occur there.  As discussed 
earlier, chemotherapeutic drugs initiate release into the cytosol of various apoptogenic 
proteins, including cytochrome c, SMAC, or AIF-1, as a result of activation of 
proapoptotic factors and inhibition of antiapoptotic factors [8].  In the cytosol, 
cytochrome c induces an apoptotic cascade by initiating formation of the apoptosome, 
which activates caspases and ultimately culminates in destruction of the cell.  The cytosol 
provides the main stage for cell execution. Though lysosomal proteases cleave most 
rigorously in an acidic environment, cathepsin D retains some activity up to a pH of 7.0, 
as will be demonstrated.  Studies have shown that cellular activation of the proapoptotic 
factor Bax, which occurs after treatment with chemotherapy drugs, initiates acidification 
 41
of the cytosol to a pH between 6.3 and 6.8 [102].  Therefore, it is possible that cathepsin 
D may retain activity in the cytosol of apoptotic cells, thus participating in cell death.   
Studies have shown that cathepsin D is relocalized to the cytosol during apoptosis 
induced by oxidative stress [91, 92].  I have hypothesized that the lysosomal protease 
cathepsin D plays an important role in chemotherapy drug-induced cell death.  Since 
processes critical to chemotherapy-induced apoptosis occur in the cytosol, I have further 
hypothesized that treatment of cells with chemotherapy drugs initiates relocalization of 
cathepsin D from lysosomes to the cytosol.  The experiments described in this chapter 
were designed to test this hypothesis. 
 
3.2. RESULTS 
This chapter investigates the subcellular localization of cathepsin D during 
chemotherapy-induced apoptosis.  Throughout this project, I have used etoposide, also 
known as VP-16, as the chemotherapy drug of choice to treat human monocytic U937 
leukemic cells or epithelial HeLa cells.  VP-16 is commonly used as an anticancer drug, 
as it elicits cell death in a variety of cancers, is relatively inexpensive, and can easily be 
used in combination with other chemotherapies [103, 104].  VP-16 contributes to the 
cellular production of double-stranded DNA breaks by stabilizing a normally transient 
DNA-topoisomerase II complex [105, 106].  The results in this chapter show that 
cathepsin D was detected in the cytosol as early as four hours following VP-16 treatment 
of cells.  Release of cathepsin D occurred prior to release of cytochrome c from the 
mitochondria or activation of caspase proteases.  Release also appeared to be selective for 
cathepsin D, as lysosomal marker proteins and cathepsin B were not detected in the 
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cytosol following VP-16 treatment.  The pancaspase inhibitor z-VAD-FMK did not 
prevent cathepsin D release, nor did the cathepsin D inhibitor pepstatin A.  Therefore, 
cathepsin D relocalization to the cytosol was not dependent on caspase or cathepsin D 
activities.  By placing this normally sequestered lysosomal enzyme in an ideal location to 
contribute to the apoptosis process, these results support the hypothesis that cathepsin D 
is important for chemotherapy-induced apoptosis.   
 
3.2.1. CATHEPSIN D  IS  ACTIVE  AT  CYTOPLASMIC  pH. 
 Cathepsin D is normally localized within a compartment with a pH of 
approximately 5.0, and not surprisingly, it is most active at acidic pH.  I have 
hypothesized that cathepsin D is released into the cytosol during chemotherapy-induced 
apoptosis.  Since the ability of cathepsin D to retain activity at the cytosolic pH of an 
apoptotic cell (typically pH 6.3-6.8) is critical to support a potential role for this enzyme 
in apoptosis execution, it was necessary to ascertain whether cathepsin D retains activity 
under a variety of pH conditions.  To examine this, U937 whole cell lysates (25 
µg/sample) were incubated with purified cathepsin D in buffers of varying pH for 1 hour 
at 37 °C, followed by immunoblotting with anti-caspase-8 antibody to assess the ability 
of cathepsin D to cleave full-length caspase-8.  Previous studies from our lab have shown 
that cathepsin D cleaves procaspase-8, though at sites distinct from the normal 
autoactivation cleavage sites.  Figure 3.1 depicts cathepsin D cleavage of caspase-8 at pH 
4.5, 6.5, or 7.0.  At pH 4.5, cathepsin D completely degraded full-length caspase-8.  At 
pH 6.5, the approximate pH of the cytosol during apoptosis, cathepsin D completely 
cleaved full-length caspase-8 to fragments of 44 kD and 47 kD. At pH 7.0, cleavage of 
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Figure  3.1.  Cathepsin D cleaves caspase-8 under various pH conditions.  Whole cell 
lysates were prepared from 5 x 106 wild-type U937 cells and incubated with either 0.2 µg 
caspase-3 or 2 µg cathepsin D in the presence or absence of 100 µM pepstatin A under a 
variety of pH conditions.  Proteins (25 µg/lane) were electrophoresed on a 10% SDS-
PAGE gel and subjected to immunoblotting for caspase-8.  Cathepsin D maintains the 
ability to cleave caspase-8 up to pH 7.0.   
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full-length caspase-8 by cathepsin D was only partial, resulting in both full-length and 
fragmented caspase-8.  Cleavage of caspase-8 under all three pH conditions was inhibited 
completely by 100 µM pepstatin A.  These results suggest that although enzyme activity 
is greatest in the highly acidic environment of the lysosome, cathepsin D does maintain 
the ability to cleave proteins at the cytosolic pH of an apoptotic cell. 
 
3.2.2. CATHEPSIN D  RESIDES  WITHIN  THE  LYSOSOMES  OF      
 UNTREATED  CELLS. 
 Studies in this chapter were designed to investigate whether cathepsin D 
undergoes relocalization from the lysosomal compartment to the cytosol following 
chemotherapy drug treatment.  Therefore, it was necessary to establish that cathepsin D is 
contained within lysosomes of healthy untreated U937 cells and to verify that the 
methodology used in this chapter was sufficient to achieve desired subcellular 
fractionation.  To accomplish these goals, a cytosolic fraction and a lysosome-enriched 
membrane fraction were prepared from untreated U937 cells using a subcellular 
fractionation method that involves homogenization of cells in a Dounce Type B tissue 
grinder followed by centrifugation (see Materials and Methods).  The Western blot for 
cathepsin D in Figure 3.2 shows that cathepsin D was contained in lysosomes.  
Lysosomal-associated membrane protein (LAMP-1), a marker of lysosomal integrity, 
was not detected in the cytosolic fraction; therefore, there was no lysosomal 
contamination in the cytosol.  Likewise, immunoblotting for β-actin, a cytosolic protein, 
showed that there was no cytosolic contamination in the lysosomal fraction.  Therefore,
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Figure  3.2.  Cathepsin D is located in the lysosomes of untreated U937 cells. 
Cytosolic and lysosomal fractions were isolated from 20 x 106 wild-type U937 cells as 
described in Materials and Methods.  Proteins (25 µg/lane) were electrophoresed on a 
12.5% SDS-PAGE gel and subjected to immunoblotting for cathepsin D, β-actin, or 
LAMP-1.  Cathepsin D was detected predominantly in the lysosomes of untreated cells. 
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the fractionation method we employed was suitable to examine chemotherapy-induced 
cathepsin D relocalization. 
 
3.2.3. CATHEPSIN D  RELOCALIZATION  OCCURS  FOLLOWING  TNF-α  OR  
STAUROSPORINE  TREATMENT 
Several studies have indicated that cathepsin D is important for cell death induced 
by stimuli such as oxidative stress, PKC inhibitors, and photodynamic therapy [92].  It 
has also been shown that cathepsin D is important for cell death induced by death 
receptor ligands such as TNF-α, IFN-γ or Fas ligand [88].  Studies involving death 
ligands utilized antisense RNA and the pharmacologic inhibitor of cathepsin D, pepstatin 
A, to show that inhibition of cathepsin D also inhibited apoptosis.  These investigations 
have not, however, investigated cathepsin D localization following death receptor 
stimulation.  Because the importance of cathepsin D in TNF-α-induced apoptosis has 
already been established, I predicted that cathepsin D would relocalize to the cytosol 
following TNF-α treatment.  Therefore, I treated U937 cells for 18 hours with 10 ng/ml 
TNF-α (concurrently with 10 µg/ml cycloheximide to sensitize cells to TNF-α) [99, 107], 
isolated cytosolic fractions, and probed for cathepsin D.  Figure 3.3.A shows that, as 
expected, cathepsin D was released into the cytosol of TNF-α-treated U937 cells, but not 
in DMSO-treated control cells.  Likewise, cathepsin D has been shown to be important in 
apoptosis induced by the protein kinase C inhibitor staurosporine [99].  When U937 cells 
were treated with 1 µM staurosporine for varying lengths of time, cathepsin D was 
detected in the cytosol as early as 6 hours following treatment, with levels continuing to 
increase up to 12 hours (Figure 3.3.B).  These results confirmed my expectation that, in 
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Figure  3.3.  Cathepsin D is released into the cytosol following TNF-α or 
staurosporine treatment.  A, 20 X 106 U937 cells were treated with 10 ng/ml TNF-α + 
10 µg/ml cycloheximide for 18 hours and harvested to obtain a cytosolic fraction.  An 
immunoblot for cathepsin D shows that cathepsin D was released into the cytosol 
following TNF-α treatment.  B, U937 cells were treated with 1 µM staurosporine for 
varying times, harvested to obtain cytosolic fractions, and subjected to immunoblotting 
for cathepsin D.  Cathepsin D was released into the cytosol 6 hours following 
staurosporine treatment and levels increased up to 12 hours.  
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U937 cells, cathepsin D relocalized to the cytosol during apoptosis [97].   
 
3.2.4. CATHEPSIN D  IS  RELOCALIZED  TO  THE  CYTOSOL  DURING  
 CHEMOTHERAPY  DRUG  TREATMENT. 
If cathepsin D is important for chemotherapy-induced apoptosis and yet remained 
completely in the lysosomal compartment following drug treatment, I would need to 
establish an argument that the lysosome plays a direct role in the apoptotic process.  This 
seems unlikely; trafficking across the lysosome’s unique membrane is tightly controlled 
to protect the cell from the interior digestive components.  However, cathepsin D 
relocalization to the cytosol following chemotherapy treatment would place the enzyme 
in a prime location to play an important role in cell death.   
To test whether chemotherapy treatment induces the release of cathepsin D into 
the cytosol, U937 cells were treated with 2 µM VP-16 for 18 hours, and a cytosolic and 
lysosome-enriched fraction were obtained via subcellular fractionation.   Following 18 
hours of VP-16 treatment, a substantial amount of cathepsin D was detected in the 
cytosol (Figure 3.4).  Because such a large amount of cathepsin D protein is expressed in 
these cells, it was difficult to discern a loss of cathepsin D in the drug-treated lysosomal 
fraction via immunoblotting (data not shown).   
To investigate the kinetics of cathepsin D release during chemotherapy treatment, 
U937 cells were treated with 2 µM VP-16 for varying lengths of time, followed by 
subcellular fractionation.  Figure 3.5 shows a Western blot of cytosolic fractions from 
both VP-16-treated and DMSO-treated samples.  Cathepsin D was detected in the 
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Figure   3.4.  Cathepsin D relocalizes from the lysosomes to the cytosol following VP-
16 treatment.  U937 cells (20x106 cells) were treated with 2 µM VP-16 or 0.1% DMSO 
for 18 hours, and cytosolic and lysosomal fractions were isolated.  Proteins (25 µg/lane) 
were electrophoresed on a 10% SDS-PAGE gel and subjected to immunoblotting with 
anti-cathepsin D antibody.  The active fragment of cathepsin D is released into the 
cytosol following VP-16 treatment.   
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Figure  3.5.  Cathepsin D is released into the cytosol over 18 hours of VP-16 
treatment.  Wild-type U937 cells were treated with 2 µM VP-16 over a period of 18 
hours.  At the indicated time points, cytosolic fractions were prepared from 20 x 106 cells.  
Cytosolic fractions (25 µg/lane) were electrophoresed on a 10% SDS-PAGE gel and 
immunoblotted for cathepsin D.  Cathepsin D was first released into the cytosol after 4 
hours of VP-16 treatment. 
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cytosol as early as 4 hours following VP-16 treatment, and the levels of cytosolic 
cathepsin D continued to rise out to 18 hours following drug treatment.   A β-actin 
immunoblot is shown as a loading control.  A small amount of cathepsin D was also 
detected in some DMSO-treated samples; this phenomenon may not be surprising, as 
DMSO is known to damage cellular membranes by increasing membrane fluidity [108, 
109]. 
In support of the Western blotting data, a cathepsin D activity assay revealed that 
cathepsin D activity was increased in the cytosol of VP-16-treated cells relative to that in 
DMSO-treated control cells (Figure 3.6).  Following 18 hours of treatment with 2 µM 
VP-16 or 0.1% DMSO, cytosolic fractions were obtained from U937 cells.  Cathepsin D 
activity in the cytosol was assessed by incubation of cytosolic samples with a fluorogenic 
cathepsin D substrate (MoCAc-Gly-Lys-Pro-Ile-Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-
NH2) for 1 hour at 37 °C.  Cleavage of this substrate, measured by fluorescence at Exλ= 
328 nm and Emλ=393 nm, is depicted in Figure 3.6.  Cytosolic cathepsin D activity, 
shown in fluorescence units, was found to increase in response to VP-16 treatment in 
U937 cells. Unfortunately, a rather high level of cathepsin D substrate cleavage was 
detected in the DMSO-treated sample as well.  This could be explained by the following:  
first, the substrate used is not completely specific to cathepsin D.  Most aspartate 
proteases, such as pepsin, proteinase A and gelatinase, have substrate specificities that are 
nearly identical to that of cathepsin D [69, 110].  They prefer to cleave dipeptide bonds 
between hydrophobic residues, particularly at Phe-Phe sequences [111].  Therefore, the 
presence of other cytosolic aspartate proteases that are capable of cleaving the cathepsin 
D substrate could lead to non-specific cleavage of the fluorogenic substrate, causing high 
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Figure  3.6.  Cathepsin D activity in the cytosol increases following VP-16 treatment.  
U937 cells (20 x 106 cells) were treated with 2 µM VP-16 or 0.1% DMSO for 18 hours 
and cytosolic fractions were prepared.  Cytosol was assayed for cathepsin D activity by 
measuring cleavage of the cathepsin D fluorogenic substrate (MoCAc-Gly-Lys-Pro-Ile-
Phe-Phe-Arg-Leu-Lys(Dnp)-D-Arg-NH2).  Cathepsin D activity in the cytosol increased 
following 2 µM VP-16 treatment.  Assays were performed in triplicate and error bars 
indicate standard deviations.  Statistical significance was determined using the 
VassarStats website (http://faculty.vassar.edu/lowry/VassarStats.html) by comparing 
cytosolic fractions from U937 cells treated with VP-16 versus cytosolic fractions from 
U937 cells treated with DMSO.  A statistically significant difference (p<0.05) in 
cathepsin D activity was observed between DMSO- and VP-16-treated samples. 
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background levels.  Second, the cathepsin D substrate is extremely photosensitive. 
Because experimental conditions were such that some degree of light exposure was 
unavoidable, the high background measured in DMSO-treated extracts may be due to 
nonspecific substrate degradation.  Nonetheless, this result, taken together with the 
immunoblot depicting the time kinetics of cathepsin D release, shows that cathepsin D 
does translocate from the lysosomes to the cytosol during the course of VP-16 
chemotherapy treatment. 
     
3.2.5. CATHEPSIN B AND LYSOSOMAL MARKERS ARE NOT DETECTED IN  
 THE CYTOSOL 
Because chemotherapy drugs cause damage to the cell, it was necessary to 
establish that the release of cathepsin D from lysosomes was not due to a generalized 
destruction of the lysosome that results in an integration of the lysosomal contents with 
cytosol.  Three different controls were used as markers of lysosomal integrity: cathepsin 
B, lysosomal membrane-associated protein (LAMP-1), and β-hexosaminidase.   
Studies of the cysteine protease cathepsin B have shown that it is released from 
the lysosome and is important during cell death resulting from various stimuli including 
TNF-α, microtubule stabilizing agents, serum deprivation, and bile-salts [67, 69, 72, 
112].  To date, a role for cathepsin B in chemotherapy-induced apoptosis has not been 
examined.  Lysosomal and cytosolic fractions obtained from U937 cells were analyzed 
via immunoblot for release of cathepsin B into the cytosol following treatment with 2 µM 
VP-16 for 18 hours.  As shown in Figure 3.7.A, after 18 hours, cathepsin B was detected 
in the lysosomal fraction, but was not detected in the cytosol.  These results suggest that 
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Figure  3.7.  Selective release of cathepsin D following VP-16 treatment.  Cytosolic 
and lysosomal fractions from U937 cells treated with 2 µM VP-16 (+) or 0.1% DMSO (-) 
were immunoblotted for cathepsin B and LAMP-1, or assayed for β-hexosaminidase 
activity. A, An immunoblot of cathepsin B shows that it was not released into the cytosol 
following VP-16 treatment.  B, The activity of β-hexosaminidase was accessed by 
measuring cleavage of the fluorogenic substrate 4-methylumberriferyl-N-acetyl-β-D-
glucosaminide dehydrate.  β-hexosaminidase was not released into the cytosol following 
VP-16 treatment.  Error bars represent standard deviations.  C, Immunoblotting with 
LAMP-1 shows that it was not released into the cytosol following VP-16 treatment. 
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cathepsin B remains in the lysosomes following chemotherapy treatment and that the 
pattern of cathepsins released during apoptosis may be either cell type- or stimulus-
specific. 
β-hexosaminidase is a resident lysosomal protein that functions normally to 
degrade terminal N-acetyl hexosamines within the cell.  It is not released from intact 
lysosomes, and therefore, is a common control for distribution of lysosomal contents 
[113, 114].  To examine lysosomal integrity, β-hexosaminidase activity in cytosolic and 
lysosomal fractions was determined by measuring cleavage of the substrate, 4-
methylumberriferyl-N-acetyl-β-D-glucosaminide dehydrate, following treatment of U937 
cells with 2 µM VP-16.  As shown in Figure 3.7.B, in untreated cells, less β-
hexosaminidase activity was detected in the cytosol compared to lysosomes.  Some non-
specific degradation of the fluorogenic substrate may have occurred, as shown by the fact 
that there was modest β-hexosaminidase activity detected in the cytosol of untreated 
cells.  More importantly, upon treatment with VP-16, there was no increase in cytosolic 
β-hexosaminidase activity even after 18 hours.  No difference in cytosolic β-
hexosaminidase activity was noted between untreated, DMSO-, and VP-16- treated 
samples, confirming the integrity of the lysosomes following drug treatment.       
The lysosomal membrane-associated protein (LAMP-1) is a heavily glycosylated 
protein that is bound to the luminal surface of lysosomal membranes, where it functions 
to protect the membrane from attack by lysosomal enzymes [115].  One would expect to 
find LAMP-1 in the cytosolic fraction only if membranes were compromised or 
fragmented during apoptosis.  Therefore, it is commonly used as a marker of intact 
lysosomes [116].  The Western blot in Figure 3.7.C shows that LAMP-1 was not detected 
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in the cytosol following VP-16 treatment.  This data provided additional confirmation 
that lysosomal membranes remained intact during the experimental time course of 
chemotherapeutic insult.  Altogether, these results show that the integrity of lysosomes is 
not compromised during VP-16-induced apoptosis and that the observed release of 
cathepsin D into the cytosol (Figure 3.5) was not the result of a general leakage of 
lysosomal contents. 
 
3.2.6. KINETICS  OF  CASPASE-3  ACTIVATION  AND  CYTOCHROME C  
RELEASE:  BOTH  OCCUR  LATER  THAN  CATHEPSIN D 
RELOCALIZATION 
One of the hallmark features of apoptosis is the activation of the caspase proteases.  
Caspases are critical for cell death induced by chemotherapeutic drugs.  Apoptotic 
processes are complex, and although caspase-independent cell death does occur, most 
cell death pathways involve caspase activation [7, 117, 118].  It was imperative, 
therefore, to assess the kinetics of cathepsin D release relative to the kinetics of 
cytochrome c release and caspase activation.  Analysis of cytosolic fractions of VP-16-
treated U937 cells for cytochrome c release revealed that cytochrome c was first detected 
in the cytosol roughly 8 hours after VP-16 treatment (Figure 3.8.A).  Additionally, U937 
cells were treated with VP-16 for varying lengths of time, and whole cells lysates were 
analyzed for the activation of caspase-3.  Active caspase-3 fragments (17 and 12 kD) 
were first detected approximately 8 hours after VP-16 treatment, presumably shortly after 
cytochrome c release (Figure 3.8.B).  Cathepsin D was first detected in the cytosol 4 
hours following VP-16 treatment (Figure 3.5), well before the release of cytochrome c or
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Figure  3.8.  Cathepsin D release into the cytosol occurs earlier than cytochrome c release or caspase-3 activation.  Wild-type 
U937 cells were treated with 2 µM VP-16 for varying times.  A, Cytosolic and mitochondrial extracts were prepared from 20 x 106 
cells and proteins (25 µg/lane) were electrophoresed on a 13% SDS-PAGE gel.  Immunoblotting with anti-cytochrome c shows that 
cytochrome c was first detected in the cytosol approximately 8 hours following VP-16 treatment.  B, Whole cell lysates were prepared 
from 5 x 106 cells at varying times and proteins (25 µg/lane) were electrophoresed on a 10% SDS-PAGE gel and immunoblotted for 
caspase-3.  Active caspase-3 fragments were first detected in the cytosol roughly 8 hours following VP-16 treatment.
the activation of caspase-3.  This data supports the hypothesis that cathepsin D may act 
upstream of caspase activation in VP-16-treated U937 cells. 
 
3.2.7. CATHEPSIN D RELOCALIZATION IS NOT INHIBITED BY CASPASE  
 INHIBITOR OR CATHEPSIN D INHIBITOR 
The appearance of cathepsin D in the cytosol of U937 cells occurs roughly 4 
hours after VP-16 treatment.  On the other hand, caspase-3 activation was not detected 
until 8 hours post-drug treatment.  To determine whether release of cathepsin D was 
dependent on the activation of caspases, U937 cells were pretreated with a general 
cysteine caspase inhibitor, z-VAD-FMK, for 1 hour at 37 °C prior to VP-16 treatment.  A 
caspase activity assay in Figure 3.9.A shows that 50 µM z-VAD-FMK was sufficient to 
completely inhibit caspase-3 activity in VP-16-treated cells.  As shown in Figure 3.9.B, 
cathepsin D release into the cytosol following VP-16 treatment was not prevented by 
caspase inhibitor.  Therefore, the cytosolic relocalization of cathepsin D was not 
dependent on caspase activation in VP-16-treated cells.   
To assess the importance of cathepsin D activity in its release, U937 cells were pretreated 
with the cathepsin D inhibitor pepstatin A for 1 hour prior to VP-16 treatment.  100 µM 
pepstatin A was sufficient to completely abrogate cathepsin D activity (data not shown).  
Figure 3.10 shows that cathepsin D relocalization was not dependent on its own activity.   
In fact, release of cathepsin D is slightly enhanced by pretreatment with pepstatin A, a 
reproducible yet puzzling phenomenon which will be addressed in the discussion.  
Nonetheless, these results illustrate that cathepsin D relocalization to the cytosol in VP- 
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 Figure  3.9.  Release of cathepsin D into the cytosol is not dependent on caspase 
activation.  Wild-type U937 cells were treated with 50 µM z-VAD-FMK for 1 hour prior 
to 2 µM VP-16 treatment for 18 hours. Cytosolic fractions were prepared from 20 x 106 
cells.  A, Proteins (20 µg/sample) from cytosolic fractions were assessed for caspase-3 
activity by measuring cleavage of the fluorogenic substrate Ac-DEVD-AFC.  Caspase-3 
activity increased substantially following VP-16 treatment, but was completely abolished 
by z-VAD-FMK.  Assays were performed in triplicate and error bars represent standard 
deviations.  B, Proteins (25 µg/lane) from cytosolic fractions were electrophoresed on a 
10% SDS-PAGE gel and subjected to immunoblotting with anti-cathepsin D antibody. 
Release of cathepsin D into the cytosol was not inhibited by the pancaspase inhibitor z-
VAD-FMK.  
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Figure  3.10.  Release of cathepsin D into the cytosol is not dependent on cathepsin D 
activity.  Wild-type U937 cells were treated with 100 µM pepstatin A prior to 2 µM VP-
16 treatment for 18 hours.  Cytosolic fractions were prepared from 20 x 106 cells. 
Proteins (25 µg/sample) were electrophoresed on a 10% SDS-PAGE gel and subjected to 
immunoblotting with anti-cathepsin D antibody.  The Western blot shows that release of 
cathepsin D into the cytosol was not prevented by pepstatin A. 
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16-treated cells was not dependent on its own activity or on the activation of caspase 
proteases.   
 
3.3. DISCUSSION 
The results in this chapter show that following treatment with the 
chemotherapeutic agent VP-16, cathepsin D is relocalized from the lysosomes to the 
cytosol.  By pinpointing the cytoplasm as the location of cathepsin D during apoptosis, 
these data provide supportive evidence for the hypothesis that cathepsin D plays an 
important role in chemotherapy-induced apoptosis.  The conundrum associated with these 
findings is that cathepsin D is normally located within an acidic compartment with a pH 
of 5.  Proteolytic enzymes contain an active binding pocket, into which “matching” 
substrates must fit correctly within the binding pocket in order for cleavage to occur.  
Alterations in pH can cause significant modifications in secondary structure when the 
protonation states of ionizable residues change, and amino acids reconfigure to form the 
most thermodynamically stable structure [119].  The result of these conformational 
changes can be a protein with a significantly altered binding pocket, often rendering the 
enzyme inactive.  Because cathepsin D is most active at acidic pH, it was necessary to 
ascertain whether activity was retained at higher pH.  While the pH of the cytosol in a 
normal cell is close to neutral, the cytosolic pH of an apoptotic cell is slightly more 
acidic, sometimes as low as 6.3 [102, 120].  It was found that cathepsin D retained the 
ability to cleave caspase-8 up to a pH of 7.0.   At a pH of 4.5, cathepsin D completely 
degraded caspase-8 so that no fragments were discernible by Western blot.  However, at 
pH 6.5, cathepsin D cleaved caspase-8 to 44/47 kD fragments.  While these fragments are 
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not the typical “active” fragments of caspase-8, the ability of cathepsin D to produce 
them shows that while cathepsin D enzymatic activity is lessened at a higher pH, it is not 
abolished.   
The reduced activity of cathepsin D at higher pH might be advantageous to 
sustaining the apoptotic process.  While destruction of an anti-apoptotic factor during 
apoptosis might not pose a problem, if fully-activated cathepsin D were to cleave a pro-
apoptotic protein, the protein might simply be destroyed rather than activated. 
Though a substantial amount of cathepsin D is released into the cytosol following 
VP-16 treatment, a large amount of cathepsin D remains within the lysosomes.  
Discerning a difference between the levels of lysosomal cathepsin D in DMSO- and VP-
16-treated cells was difficult via Western blot.  The release of only a small portion of the 
total cathepsin D pool still may have very significant consequences for the cell.  The 
cathepsin D protein is expressed in very high levels in virtually all cell types [82].  
Therefore, even if only a small percentage of total cathepsin D is released into the 
cytosol, it still may represent a substantial amount of protein.  Additionally, only a small 
amount of enzyme is required to initiate an enzymatic cascade.  For instance, only a 
fraction of the total amount of mitochondrial cytochrome c must be released from 
mitochondria to induce apoptosis [121-125].  If the function of cathepsin D is to cleave 
an apoptotic regulatory factor to initiate a downstream process, only a small amount of 
cathepsin D would be necessary to initiate enzymatic progression.   
It is also possible that the appearance of cathepsin D in the cytosol following VP-
16 treatment results from increased expression of a cytosolic form of cathepsin D that 
lacks lysosomal targeting signals.  While this possibility may be unlikely as the cathepsin 
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D protein contains several lysosomal targeting signals, use of the protein translation 
inhibitor cycloheximide in relocalization experiments would verify whether cathepsin D 
appearance in the cytosol is directly due to relocalization of cathepsin D from the 
lysosomes.  
In addition to investigating localization of cathepsin D during chemotherapy-
induced apoptosis, the localization of other key lysosomal proteins was also examined.  
β-hexosaminidase is a resident lysosomal protease that functions in the lysosomes to 
degrade terminal N-acetyl hexosamines within the cell [113].  Because β-hexosaminidase 
is not released from intact lysosomes, it is commonly used as a marker of lysosomal 
integrity [126-128].  Cleavage of a small amount of β-hexosaminidase substrate was 
detected in the untreated cytosolic fraction, probably due to nonspecific cleavage of the 
fluorogenic substrate.  Importantly, β-hexosaminidase activity in the cytosol was 
significantly less than in the lysosomes.  Moreover, cytosolic β-hexosaminidase activity 
did not increase even after 18 hours of drug treatment, and there were no differences 
between DMSO- and VP-16- treated samples. The absence of increased β-
hexosaminidase in the cytosol following VP-16 treatment suggests that lysosomes remain 
intact during chemotherapy treatment.  
The cytosolic presence of another lysosomal protein, LAMP-1, following VP-16 
treatment was also examined.  LAMP-1 is a membrane protein which is bound to 
lysosomal membranes to protect them from attack from the digestive enzymes of the 
lysosome [115].  The absence of LAMP-1 in the cytosol suggests that lysosomal 
membranes remain intact during chemotherapy-induced damage.  This data, taken in 
conjunction with the β-hexosaminidase data, strongly suggests that lysosomal integrity is 
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preserved during VP-16 induced apoptosis and that cathepsin D release is not due to a 
general rupture of the lysosome and release of lysosomal contents. 
If lysosomes do not release all of their contents during chemotherapy-induced 
apoptosis, then how is cathepsin D released?  Bidere et al. [99] have shown that during 
staurosporine-induced apoptosis, lysosomal proteins are released in a size-selective 
fashion, as preloaded FITC-dextran molecules under 70 kD were released from 
lysosomes, while larger dextrans were not.  However, relocalization of lysosomal 
proteins following VP-16 treatment may not be size-dependent since the 34 kD cathepsin 
D protein was released but the 31 kD cathepsin B protein was not.  It is possible, 
however, that if cathepsin B exists in a complex within lysosomes, its apparent molecular 
weight may appear much higher.  To rule out a size-dependency in the release of 
lysosomal proteins following VP-16 treatment, dextran experiments could be conducted 
using VP-16 as in the case of staurosporine [99]. 
Although the mechanism of cathepsin D release remains unclear, and was not 
investigated in this project, there are several possible mechanisms.  A conformational 
change resulting from enzyme activation might allow cathepsin D to adopt a temporary 
unfolded structure that could allow it to pass through the lysosomal membrane.  
Proteolytic processing of the cathepsin D enzyme occurs during activation to the 34 kD 
fragment.  Though active cathepsin D is always present within the lysosome, it is possible 
that VP-16 treatment leads to slight additional processing that alters the structure of 
cathepsin D, allowing it to pass through the lysosomal membrane.  Alternatively, the 
heavily glycosylated side chains of cathepsin D contain many potential phosphorylation 
sites, and modulation of these sites may play a role in release [79].  It is possible that 
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removal of the cathepsin D phosphorylation sites via cleavage may alter the structure of 
cathepsin D so that it no longer possesses “recognition signals” that are necessary for 
sequestration in the lysosomes.  To date, however, no one has offered experimental data 
to delineate a mechanism for specific cathepsin D release from the lysosomes. 
Evidence does exist to indicate that cathepsin B is specifically released from the 
lysosomes following stimulation with TNF-α [70].  However, I did not observe cathepsin 
B release in response to VP-16 treatment, suggesting that it is not involved in etoposide-
induced apoptosis.  It is likely that the pattern of proteolytic enzymes released from 
lysosomes during apoptosis varies depending on both the apoptotic stimuli and on the cell 
type.  
Although VP-16-induced caspase activation occurred at a later time point than 
release of cathepsin D into the cytosol, it was important to investigate whether caspase 
activation impacted cathepsin release.  In addition to acting as executioners during 
apoptosis, some caspases further promote cell death by participating in feedback 
activation loops. For instance, though caspase-3 is activated downstream of caspase-9 
during apoptosis, caspase-3 can in turn cleave caspase-9 to further promote amplification 
of the caspase cascade [129, 130].  In one study, cytochrome c release initiated by 
etoposide was found to occur in two stages: an early, modest release of cytochrome c 
promoted activation of caspase-9 and caspase-3, while late cytochrome c release resulted 
in a drastic change in mitochondrial membrane potential and substantial loss of 
mitochondrial cytochrome c.  Interestingly, the late stage cytochrome c release was 
inhibited by the caspase inhibitor z-VAD, suggesting that a feedback loop causes 
caspases to induce further mitochondrial dysfunction and late stage cytochrome c release 
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[17]. One of the potential roles of cathepsin D in chemotherapy-induced apoptosis may 
be to enhance caspase activation either by direct cleavage or by stimulation of upstream 
apoptotic factors that lead to caspase activation.  To investigate whether the release of 
cathepsin D from lysosomes was dependent on caspase feedback activation, cells were 
treated with the pancaspase inhibitor z-VAD-FMK prior to treatment with VP-16.  The 
data in this chapter showed that caspase inhibition did not prevent cathepsin D 
relocalization to the cytosol.  Cathepsin D release from lysosomes, therefore, is not 
dependent on caspase activation.   
To investigate whether cathepsin D relocalization was dependent on its own 
activity, cells were treated with 100 µM pepstatin A, a dose sufficient to inhibit cathepsin 
D activity in the cell, prior to VP-16 treatment.  Pepstatin A contains an unusual statyl 
residue (4-amino-3-hydroxy-6-methylheptanoic acid) that is necessary for irreversible 
binding of the inhibitor to the active enzyme [131, 132].  The data in this chapter suggests 
that pepstatin A does not prevent release of cathepsin D from the lysosomes; in fact, 
pepstatin A modestly enhanced cathepsin D release.  This is a puzzling phenomenon that 
has not been noted in other studies.  It was suggested earlier in this discussion that 
cleavage of cathepsin D might temporarily alter the enzyme’s structure so that it can pass 
easily out of the lysosomes.  It is possible that, if pepstatin A binds to active cathepsin D, 
it might “freeze” this structure so that it remains in an advantageous conformation for 
release.  Further studies are necessary to determine the importance of pepstatin A on the 
cytosolic relocalization of cathepsin D following chemotherapy treatment. 
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3.4. CONCLUSION 
In conclusion, the data presented in this chapter have shown that cathepsin D 
was not present in the cytosol of untreated U937 cells.  Cathepsin D was released 
from the lysosomes about four hours after VP-16 treatment, prior to release of 
cytochrome c or activation of caspase-3.  Cytosolic accumulation of the lysosomal 
proteins β-hexosaminidase, LAMP-1, and cathepsin B was not observed, suggesting 
that the release of cathepsin D is the result of a selective process.  Cathepsin D 
release was not dependent on caspase activity, nor was it dependent on its own 
activity.  These results provide support for the hypothesis that cathepsin D is 
important in chemotherapy-induced apoptosis by placing cathepsin D at the cellular 
location of important apoptosis signaling events. 
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4. DOWNREGULATION  OF  CATHEPSIN D  INHIBITS 
CHEMOTHERAPY-INDUCED  CELL  DEATH 
4.1. INTRODUCTION 
I have hypothesized that cathepsin D is important in chemotherapy-induced 
apoptosis.  To directly test this hypothesis, I chose to utilize RNA interference 
technology to downregulate expression of the cathepsin D protein in U937 and HeLa 
cells to determine whether cathepsin D downregulation provides protection against 
chemotherapy-induced cell death.   
 
4.1.1. COMMON  METHODS  USED  TO  DOWNREGULATE  PROTEIN   
 EXPRESSION 
There are advantages and disadvantages to common methodologies for 
downregulating the expression or activities of proteins.  Before the conception of gene-
targeting methods, the primary means of enzyme inhibition was use of a pharmacologic 
inhibitor.   In fact, pharmacologic inhibitors such as DEVD, z-VAD, and IETD are still 
commonly used to inhibit caspase proteases [27, 133, 134].   Using pharmacologic 
inhibitors is advantageous in several ways.  Many are cell permeable, and by requiring 
only a short incubation with cells to confer their inhibitory effects, they are easy to use.  
The mechanism of most protease inhibitors is to bind the active site of the enzyme, thus 
preventing substrate entry and binding [135].  However, because many enzymes have 
analogous substrate specificities, pharmacologic inhibitors are often not specific for one 
enzyme and can even inhibit an entire family of enzymes.  Many of the studies that have 
investigated the importance of cathepsin D in apoptosis have employed the 
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pharmacologic inhibitor pepstatin A.  For example, Deiss et al. [88] utilized pepstatin A 
to examine the importance of cathepsin D in TNF-α-, IFN-γ-, and Fas/APO-1 ligand-
induced apoptosis.  Similarly, Bidere et al. [99] found that staurosporine-induced cell 
death was delayed by pepstatin A.  The serious problem with using pepstatin A to study 
the effects of cathepsin D is that pepstatin A inhibits several aspartic proteases, including 
renin, pepsin, and proteinase A [131, 132].  Thus, the promiscuity of pepstatin A 
precludes drawing definitive conclusions about the specific role of cathepsin D. 
Technology developed in the 1980s allowed researchers to target enzymes at the 
level of gene expression by introducing an antisense molecule complementary to the 
mRNA of the gene of interest [136].  Once introduced into the cell, the antisense 
molecule binds to the complementary mRNA sequence to form a duplex, and thus 
prevents translation of the gene product.  Antisense-mediated protein downregulation can 
be inefficient, due partly to the stoichiometry of the methodology [140].  One molecule of 
antisense cDNA is required to silence one mRNA target.  Therefore, large numbers of 
antisense molecules are required to elicit efficient silencing.  
 
4.1.2. RNA  INTERFERENCE 
Direct cellular introduction of small interfering RNAs (siRNAs) has overcome 
many of the hurdles associated with the inefficiency of antisense RNAs and the 
cytotoxicity associated with long double-stranded RNA molecules.  siRNAs are small 
double-stranded RNAs that, like antisense and long dsRNA, target and degrade mRNA 
homologous to the siRNA sequence [137, 138].  RNA interference (RNAi) was first 
observed inadvertently by plant biologists who were attempting to enhance the petal color 
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of petunias by introducing a promoter sequence for chalcone synthase, a pigment-
inducing gene.  Instead of generating brighter flowers, the plants produced flowers 
completely devoid of color [139, 140].  Though these results puzzled scientists at the 
time, the discovery that direct injection of a double-stranded RNA into the nematode C. 
elegans posttranscriptionally silenced the genes homologous in sequence to the injected 
dsRNA enlightened researchers to the world of RNA interference [141, 142].  
There are two commonly accepted methods for producing siRNAs in cells.  In the 
first method, short (typically 21-nucleotide) siRNA duplexes with 2-nucleotide 3’-
overhangs are synthesized and transfected into cells.  The duplexes then directly activate 
the cellular RNAi system for silencing of homologous mRNA targets.  The advantage of 
this method is that siRNA-mediated protein downregulation occurs within 1-2 days of 
transfection.  The disadvantage of direct siRNA delivery is that protein downregulation is 
transient (5-6 days) because the siRNAs are degraded quickly.  Additionally, because 
cells must be transfected prior to each experiment, the degree of protein downregulation 
may change due to variable transfection efficiency.  In the second method, a plasmid or 
virus that codes for an oligonucleotide homologous to a sequence of interest and a 
selectable marker such as hygromycin B, puromycin, or neomycin is transfected into 
cells.  Vectors used for siRNA production typically contain an RNA polymerase III 
promoter that is capable of producing large numbers of the siRNAs.  The transfected cells 
are cultured in the presence of the appropriate selection media, and presumably only cells 
that stably express the transfected plasmid will grow.  These cells are capable of 
continually producing the appropriate siRNAs to elicit specific protein downregulation.  
While siRNA clones may take weeks to grow via this method, once clones are 
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established, their levels of protein downregulation presumably remain stable.  For the 
experiments described in this chapter, I chose to establish stable siRNA clones that 
downregulate cathepsin D expression in both HeLa cells and U937 cells. 
There are distinct advantages to using siRNAs to silence cathepsin D.  First, because 
of their small size (typically not more than 21-23 nucleotides in length), siRNAs do not 
activate the mammalian dsRNA-inducible interferon system that is normally initiated in 
response to cellular introduction of long double-stranded RNA [137, 138].  This 
interferon response can lead to alteration of cellular phenotype or cytotoxicity by causing 
nonspecific gene suppression.  Second, siRNA-mediated gene suppression can be highly  
efficient [140].  In this chapter, downregulation of cathepsin D using siRNA was 
measured to be at least 95% via Western blotting and cathepsin D activity assays.  Third, 
it is possible to search for and use nucleotide sequences that are homologous only to the 
gene of interest.  Therefore, the specificity of downregulation using siRNAs can be better 
than the specificity of enzyme inhibition using a pharmacologic inhibitor such as 
pepstatin A.   
Figure 4.1 outlines a schematic model for the molecular mechanism of RNA 
interference. Double-stranded RNAs are introduced to the cell and are cleaved by the 
Dicer endonuclease to 21-nucleotide duplexes [138, 143].  In the cell, these duplexes 
recruit and activate the RNA-induced silencing complex (RISC), a multiprotein 
endonuclease complex that is responsible for specific degradation of target mRNA [144].  
Though the mechanism by which siRNA constrains RISC is not clearly understood, it is 
known that siRNAs shuttle RISC to homologous mRNAs, where the antisense strand
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Figure  4.1.  Schematic diagram of the siRNA-induced silencing mechanism.  Double-
stranded RNA enters the cell and is cleaved by the endonuclease Dicer to 21-25 
nucleotide small interfering RNAs (siRNAs) with 2-nt 3’ overhangs.  These small 
dsRNAs recruit and associate with the endonuclease complex RISC.  By a process that is 
poorly understood, the siRNAs unwind and guide RISC to complementary mRNAs.  A 
base-pairing mechanism between the mRNA and siRNA promotes activated RISC to 
cleave and degrade target mRNAs.  
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of the siRNA duplex unwinds and base-pairs with complementary mRNAs [138, 140, 
144].  Activated RISC cleaves and degrades sequence-specific mRNA, resulting in gene 
silencing. 
Ideal siRNA nucleotide sequences have several characteristics.  Most are 21-23 
nucleotides in length, with 2 nucleotide “overhangs” at the 3’ ends [137].  The overhangs 
are typically a TT sequence, which acts as an efficient cleavage recognition sequence for 
Dicer, as a recognition sequence for RISC, and also as a feature that renders the siRNA 
itself more resistant to further degradation by nucleases [138, 145].  Appropriate target 
sequences in the gene exist in the open reading frame of the mRNA, at least 50-100 
nucleotides downstream of the start codon [145].  Most importantly, it is critical that the 
target sequences are only found in the gene of interest so that silencing is specific. 
   
4.2. RESULTS 
4.2.1. DESIGN  AND  PREPARATION  OF  CATHEPSIN D  siRNA      
 OLIGONUCLEOTIDES  
To downregulate the cathepsin D protein, target sequences at varying locations in 
the cathepsin D mRNA were chosen using criteria from the Ambion siRNA target finder 
(Figure 4.2.A) [146].  Five oligonucleotides were designed to target the cathepsin D 
mRNA (Figure 4.2.B).  For each siRNA sequence, two 62-63-nt oligonucleotides were 
constructed with a 9-nt “loop” separating a 21-nt sense sequence and its complementary 
sequence, a 5-6 nucleotide poly(T) sequence at the 3’ end, and Bam HI and Hind III 
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A 
nt 144:  5’-AAAGGCCCCGTCTCAAAGTAC-
nt 213:  5’-AAGAACTACATGGACGCCCAG-
nt 330:  5’-AAACTGCTGGACATCGCTTGC-
nt 648:  5’-AACCTGATGCAGCAGAAGCTG-
nt 1425: 5’-AAATGCTGCCTGCCTGTCTGT-
B 213 33 64 142144 
 17 34 
5’-Nontranslated 3’-Nontranslated
Cathepsin D mRNA  
 
 
 
Figure  4.2.  Nucleotide sequences selected as silencing targets in the cathepsin D 
mRNA.  A, The five 21-nucleotide cathepsin D siRNA sequences. The 144 siRNA 
sequence targeting codons 50-55 in human cathepsin D mRNA was the only sequence to 
evoke efficient downregulation of cathepsin D protein.  B, A schematic representation of 
the five sites targeted for silencing in the cathepsin D mRNA is shown.  
 
 
 
 77
restriction sites at the ends. (Figure 4.3).  Typically, to produce stable siRNA molecules 
in cells, expression vectors with dual promoters are used to express the two strands of the 
siRNA.  However, this project utilized hairpin structure siRNAs because only one vector 
is necessary for expression of the entire siRNA oligonucleotide and folding into the 
double-stranded structure is more efficient [147].  In our case, the oligonucleotide 
sequences were designed to generate Bam HI or Hind III restriction sites at the 5’ and 3’ 
ends, respectively, of the annealed insert fragments to facilitate insertion into the 
silencing vector.  The oligonucleotides were ligated and annealed into the pSilencer 2.1-
U6 hygro vector, which contains a hygromycin B resistance gene for selection in cells.  
Hygromycin B is an aminoglycoside antibiotic that inhibits protein synthesis by 
interfering with translocation of ribosomes [148].  The hygromycin resistance gene 
initiates phosphorylation of hygromycin, thus inactivating it and conferring antibiotic 
resistance.  The pSilencer 2.1-U6 vector also utilizes a U6 RNA polymerase III promoter, 
frequently used in siRNA production because it is a very strong promoter capable of 
driving expression of large amounts of siRNAs (www.ambion.com).  Figure 4.4 depicts 
the pSilencer 2.1-U6 hygro vector map.   
  
4.2.2. CATHEPSIN D  IS  DOWNREGULATED  IN  U937  AND  HELA  CELLS    
 BY siRNA 
Five oligonucleotides corresponding to unique sequences in the cathepsin D 
mRNA were subcloned into pSilencer vector 2.1-U6, then transfected into HeLa and 
U937 cells using the GenePORTER2 transfection reagent (see Materials and Methods). 
Stably transfected cells that grew in the presence of hygromycin B were expanded in cell  
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Figure  4.3.  Design of the 144 CD siRNA oligonucleotide hairpin loop.  Oligos are 
designed by connecting a 21-nucleotide siRNA sequence to the complementary sequence 
with a 9-nucleotide “loop” sequence.  Bam HI and Hind III restriction sites are added to 
the ends for ligation into the vector.  When transcribed, the siRNA structure forms a 
double-stranded structure that is capable of recruiting the RISC complex in vivo.   
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Figure  4.4.  Vector map of pSilencer 2.1-U6 hygro.  siRNA oligonucleotides were 
ligated into pSilencer between the Bam HI and Hind III restriction sites.  Following 
transfection of U937 and HeLa cells, cell lines harboring the siRNA constructs were 
selected in media containing 250 µM hygromycin B. 
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culture, and independent clonal lines were isolated by limiting dilution (U937) or colony 
cloning (HeLa).  Additionally, a pSilencer 2.1 U-6 construct containing a 21-nucleotide 
siRNA sequence with no homology to any known gene was transfected into HeLa and 
U937 cells as a control.  Of the five transfections, three (containing siRNA sequences 
directed towards nucleotides-144, -248, and -1425) produced viable clones.  These clones 
were expanded in hygromycin B-containing media and whole cell lysates from the clones 
were examined for the presence of cathepsin D.  Cathepsin D downregulation was 
successfully achieved in the clones containing a sequence directed towards nucleotides 
144 -164 of cathepsin D mRNA (Figure 4.5).  In Figure 4.5.A, Western blotting was used 
to compare cathepsin D protein expression in wild-type HeLa cells, HeLa cells 
expressing the control siRNA sequence (control siRNA/HeLa), and HeLa cells 
expressing the 144 cathepsin D (CD) siRNA (144 CD siRNA/HeLa). While cathepsin D 
expression in cells harboring the control siRNA was unaffected, cathepsin D expression 
in cells containing the 144 CD siRNA was downregulated by greater than 95% 
(densitometric scanning, not shown).  Control immunoblots for caspase-8, caspase-3, β-
actin (Figure 4.5.A), PARP, and XIAP (data not shown) verified that expression of these 
proteins was unaffected and that downregulation of cathepsin D was specific.  In support 
of this data, a cathepsin D enzymatic activity assay of whole cell lysates showed that 
cleavage of the cathepsin D fluorogenic substrate MoCAc-Gly-Lys-Pro-Ile-Phe-Phe-Arg-
Leu-Lys(Dnp)-D-Arg-NH2 was inhibited in two different HeLa cell clones expressing the 
144 CD siRNA (Figure 4.5.B).  
In U937 cells, immunoblotting reveals that cells harboring the 144 CD siRNA 
(144 CD siRNA/U937) also exhibited greater than 95% downregulation of cathepsin D 
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Figure  4.5.  siRNA-mediated specific downregulation of cathepsin D in U937 and 
HeLa cells.  A, Cathepsin D protein expression is downregulated in clonal HeLa cells 
transfected with pSilencer plasmid containing the cathepsin D (CD) 144 siRNA sequence 
(see Materials and Methods).  The control lane depicts a clonal HeLa cell line transfected 
with pSilencer plasmid containing a control sequence that bears only limited homology 
with all known sequences in the human genome.  Whole cell extracts from wild-type 
HeLa cells, control siRNA/HeLa cells, and 144 CD siRNA/HeLa cells were subjected to 
immunoblotting with cathepsin D, caspase-8, caspase-3, or β-actin antibody.  The data 
show specific downregulation of cathepsin D protein in the 144 CD siRNA/HeLa cells.  
B, Cathepsin D enzymatic activity was assayed in whole cell extracts (5 µg per sample) 
of wild-type HeLa cells and two clonal HeLa cell lines expressing the 144 CD siRNA 
(clones A and B).  Enzymatic activity was measured as described in Materials and 
Methods using the fluorogenic substrate MoCAc-Gly-Lys-Pro-Ile-Phe-Phe-Arg-Leu-
Lys(Dnp)-D-Arg-NH2.  The depicted values represent the mean of triplicate assays and 
error bars represent standard deviations.  C, Cathepsin D expression is also 
downregulated in clonal U937 cells transfected with pSilencer plasmid containing the 
144 CD siRNA sequence.  Whole cell extracts from wild-type U937 cells, control 
siRNA/U937 cells, and 144 CD siRNA /U937 cells were subjected to immunoblotting 
with cathepsin D, caspase-8, caspase-3 or β-actin antibody.  D, Whole cell extracts from 
two clonal HeLa cell lines (clones A and B) and one clonal U937 cell line expressing the 
144 CD siRNA were subjected to immunoblot analysis for the aspartic cathepsin 
protease, cathepsin E.  Cathepsin E was not downregulated by the 144 CD siRNA in 
HeLa cells.  Expression of cathepsin E was not detected in parental, wild-type U937 
cells.   
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protein expression as compared to wild-type U937 cells and U937 cells containing the 
control siRNA sequence (Figure 4.5.C and densitometric scanning).  Immunoblots for 
caspase-8, caspase-3, and β-actin showed that, as with HeLa cells, the 144 CD siRNA 
specifically downregulated the cathepsin D protein in U937 cells.  Expression of 
cathepsin E, the closest related enzyme and the only other known aspartate cathepsin, 
was unaffected in two different HeLa clones expressing 144 CD siRNA (Figure 4.5.D).  
Cathepsin E was not detected in wild-type U937 cells or in 144 CD siRNA/U937 cells 
(Figure 4.5.D) 
To ensure that downregulation of cathepsin D did not alter the metabolic phenotype 
of these cells, healthy U937 cells were plated at a density of 1 x 105 cells/ml and cell 
growth was assessed under normal cell culture conditions for 4 days.  Figure 4.6 
demonstrates that the growth kinetics of the 144 CD siRNA/U937 cell were identical to 
that of wild-type U937 cells.  Similar results were seen in HeLa cells (data not shown).  
These results confirm that the use of RNAi is an efficient method to downregulate 
cathepsin D expression in both suspension leukemic cells (U937) and adherent epithelial 
cells (HeLa). 
 
4.2.3. DOWNREGULATION  OF  CATHEPSIN D  BY  siRNA  INHIBITS  CELL  
 DEATH  INDUCED  BY  VARIOUS  APOPTOTIC  STIMULI    
Cathepsin D has been shown to play a role in apoptosis induced by death ligands 
such as TNF-α [88, 149], by oxidizing agents such as naphthazarin [90-93], by the 
protein kinase C inhibitor staurosporine [98, 99], and by sphingosine, a potent inducer of 
ceramide production [51, 97].  If cathepsin D is important for apoptosis induced by TNF- 
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Figure  4.6.  Growth kinetics of wild-type U937 and 144 CD siRNA/U937 cells.  Wild-
type U937 cells and 144 CD siRNA/U937 cells were plated at a density of 1 x 105 
cells/ml and cultured under normal conditions (see Materials and Methods).  At the 
indicated time points, aliquots of cells were removed for cell counting.  The growth 
curves shows that the growth of the 144 CD siRNA/U937 clone is identical to that of 
wild-type U937 cells. 
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 α, naphthazarin, staurosporine, or sphingosine, then I predicted that cathepsin D 
downregulation would inhibit cell death following these treatments.  To test this 
hypothesis, the kinetics of cell death were assessed via trypan blue exclusion assays 
following treatment with apoptotic stimuli in wild-type cells, cells expressing the control 
siRNA, and cells expressing the 144 CD siRNA.  As described in Materials and Methods, 
cells were treated with apoptotic stimuli and at various time points, aliquots of cells were 
removed for analysis by trypan blue dye exclusion.  As shown in Figure 4.7, 
downregulation of cathepsin D did impact cell death following several different 
treatments in both HeLa and U937 cells.  HeLa cells were treated with 10 ng/ml TNF-α 
in combination with 10 µg/ml cycloheximide.  After 48 hours of TNF-α treatment, 30% 
of wild-type HeLa cells and control siRNA/HeLa cells remained viable (Figure 4.7.A).  
Strikingly, roughly 90% of 144 CD siRNA/HeLa cells remained viable after 48 hours of 
TNF-α treatment.  Likewise, downregulation of cathepsin D in HeLa cells protected 
against cell death induced by 1 µM napthazarin and 10 µM sphingosine (Figure 4.7.A).  
By contrast, downregulation of cathepsin D expression in HeLa cells did not protect 
against cell death induced by the PKC inhibitor staurosporine (data not shown).    
Downregulation of cathepsin D in U937 cells resulted in protection against cell 
death induced by a variety of stimuli as well.  Figure 4.7.B shows that cell death was 
significantly inhibited in 144 CD siRNA/U937 cells following treatment with 10 ng/ml 
TNF−α + 10 µg/ml cycloheximide, 2 µg/ml TRAIL, 1 µM staurosporine, or 4 µM 
naphthazarin.  These results confirm that the siRNA clones are functional and that, in our 
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 e stress-, and ceramide-induced cell death is inhibited by siRNA-mediated 
La cells were exposed for varying lengths of time to 10 ng/ml TNF-α + 10 µg/ml 
 µM sphingosine.  At the indicated timepoints, aliquots of cells were removed and 
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lls were treated with 2 ng/ml TNF-α + 5 µg/ml cycloheximide, 2 µg/ml TRAIL, 1 µM 
r varying lengths of time and cell viabilities determined as in Panel A.  Statistical 
in Panel A. 
cell systems, cathepsin D plays an important role in apoptosis induced by TNF-α, 
TRAIL, oxidative stress (naphthazarin), and ceramide (sphingosine). 
 
4.2.4. DOWNREGULATION   OF  CATHEPSIN D  BY  siRNA  INHIBITS  
 CHEMOTHERAPY-INDUCED  APOPTOSIS 
In this section, the effects of cathepsin D downregulation on chemotherapy-
induced apoptosis were assessed.  If cathepsin D is important for chemotherapy-induced 
cell death, as my hypothesis states, then it is expected that cells that do not express the 
cathepsin D protein would exhibit significant protection against chemotherapy drugs.  
Figure 4.8 illustrates the effects of multiple chemotherapy drugs on cell viability in wild-
type cells, cells expressing control siRNA, and cells expressing 144 CD siRNA.  144 CD 
siRNA/HeLa cells were found to be significantly protected against cell death induced by 
100 µM VP-16 over 48 hours of treatment (Figure 4.8.A). 144 CD siRNA/HeLa cells 
were also protected against cell death by the chemotherapy drugs 5-fluorouracil and 
cisplatin, particularly late in apoptosis.  To verify that the protection observed in these 
cells was not unique to this clone of transfected cells, a second HeLa cell clone harboring 
CD siRNA (144 B) was tested and found to exhibit similar responses to all three 
chemotherapy drugs (Figure 4.9).  U937 cells expressing the 144 CD siRNA also were 
significantly protected against 2 µM VP-16-induced cell death throughout the course of 
the 48-hour treatment (Figure 4.8.C).  An inherent, marked resistance of wild-type U937 
cells to 5-fluorouracil and cisplatin precluded inclusion of studies with these drugs in 
U937 cells.  A comprehensive table of results from the trypan viability experiments in 
HeLa and U937 cells is shown in Figure 4.10.  The first column in the table indicates the 
type of stimulus used to induce cell death.  The second column indicates whether the 
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Figure  4.8.  Chemotherapy-induced cell death is inhibited by siRNA-mediated downregulation of cathepsin D.  A, HeLa cells 
were exposed for varying lengths of time to 100 µM VP-16, 5 µM 5-fluorouracil, or 10 µM cisplatin.  At the indicated timepoints, 
aliquots of cells were removed and assayed for viability by trypan blue exclusion.  For each data point, quadruplicate counts were 
performed using a minimum of 100 cells per count.  Error bars represent standard deviations.  Control, untreated cultures always 
maintained greater than 97% viability out to 48 hours.  B, U937 cells were treated with 2 µM VP-16 for varying lengths of time and 
cell viabilities determined as in Panel A.  Statistical significance was determined as described in Figure 4.7.
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Figure  4.9.  Two different 144 CD siRNA/HeLa cell clones (A and B) protect against 
5-fluorouracil- and VP-16-induced cell death.  Two different transfected clones of 
HeLa cells harboring the 144 CD siRNA were exposed for varying lengths of time to 5 
µM 5-FU or 100 µM VP-16.  At the indicated timepoints, aliquots of cells were removed 
and assayed for viability by trypan blue exclusion.  For each data point, quadruplicate 
counts were performed using a minimum of 100 cells per count.  Error bars represent 
standard deviations.  Control, untreated cultures always maintained greater than 97% 
viability out to 48 hours.  Statistical significance was determined as described in Figure 
4.7.  As shown, both 144 CD siRNA/HeLa clones exhibited significant protection from 5-
FU- and VP-16-induced cell death. 
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Figure  4.10.  Summary of cathepsin D siRNA protection against cell death induced 
by a variety of stimuli. 
stimulus was capable of causing apoptosis in wild-type cells.  The third column indicates 
the relative degree of protection conferred by the 144 CD/siRNA.  A minus sign indicates 
that the cathepsin D siRNA offered no protection against apoptosis.  One plus sign 
indicates that cell death was inhibited between 15 and 30% by cathepsin D 
downregulation (% difference = control siRNA – 144 CD siRNA), while two plus signs 
indicate that inhibition of cell death was greater than 30%.  These results demonstrate 
that downregulation of cathepsin D protein expression in both HeLa cells and U937 cells 
confers significant protection against apoptosis induced by chemotherapy drugs.  
Together these findings provide strong support for my hypothesis that cathepsin D is 
important for chemotherapy-induced cell death.   
 
4.3. DISCUSSION 
There are several advantages associated with using stable siRNA clones to 
downregulate the cathepsin D protein compared to antisense-mediated downregulation or 
pharmacologic inhibition.  The only maintenance required to sustain the stable CD 
siRNA clones was to culture them in media containing hygromycin B.  With a stable 
clone, cathepsin D downregulation does not vary throughout the course of experiments, 
whereas the efficiency of inhibition by a pharmacologic inhibitor or transient transfection 
may vary throughout the experimental time course and from experiment to experiment.  
Also, the siRNA oligonucleotides were found to downregulate cathepsin D extremely 
efficiently (>95%), more so than downregulation expected with an antisense RNA 
approach.  
 96
Nonetheless, problems can arise when using RNA interference strategies.  
Recently, reports have suggested nonspecific downregulation of other genes during the 
RNAi process, presumably due to siRNA duplex binding nonspecifically to sequences 
which are not 100% homologous to the targeted sequence [150].  Therefore, great care 
must be taken to ensure that critical proteins in the pathway of interest (in our case, 
apoptosis) are not also inadvertently silenced.  We addressed this issue by ensuring that 
expression of key apoptotic proteins (caspase-3, caspase-8), as well as the aspartic 
protease, cathepsin E, was not altered in the silencing process.  Additionally, care was 
taken to ensure that the growth properties of the siRNA clones were similar to that of the 
wild-type cells.    
The results of this chapter are summarized in Figure 4.10.  The data support the 
hypothesis that cathepsin D is important not only in death ligand- and oxidative stress- 
induced apoptosis, but also in chemotherapy-induced apoptosis.  Though protection 
against cell death was conferred with most treatments in both HeLa and U937 cells 
harboring the 144 CD siRNA, the degree of protection varied.  For instance, 144 CD 
siRNA/HeLa cells were not protected against staurosporine–induced cell death and 144 
CD siRNA/U937 cells were protected only to a small degree.  Bidere et al. [99] have 
reported that inhibition of cathepsin D using pepstatin A in T lymphocytes markedly 
protected against staurosporine-induced cell death..  Thus, the importance of cathepsin D 
in cell death may vary depending on both the cell type and the stimulus used.  However, 
for the chemotherapy drugs I studied (VP-16, cisplatin, and 5-fluorouracil), drug-induced 
apoptosis was always inhibited by the 144 CD siRNA.  As VP-16 efficiently induces 
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death in both U937 cells and HeLa cells, it was utilized to further investigate the 
mechanism of cathepsin D-induced cell death (Chapter 5).  
 
4.4. CONCLUSION 
The results from this chapter demonstrate that the cathepsin D protein can 
be efficiently and specifically downregulated using RNA interference.  Cells 
exhibiting downregulation of cathepsin D were protected against a variety of 
apoptotic stimuli, including death receptor activation, oxidative stress, ceramide, 
and inhibition of PKC.  Importantly, downregulation of cathepsin D protected cells 
against chemotherapy-induced cell death, supporting the hypothesis that cathepsin 
D is important in this cell death pathway. 
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 5. THE ROLE OF CATHEPSIN D  IN  CYTOCHROME C  RELEASE  
 AND  CASPASE  ACTIVATION  FOLLOWING  CHEMOTHERAPY  
 TREATMENT 
 
5.1. INTRODUCTION 
The data in this project have thus far established that, following chemotherapeutic 
stimuli such as VP-16, lysosomal cathepsin D is released into the cytosol prior to 
cytochrome c release and caspase activation.  The importance of cathepsin D in 
chemotherapy-induced apoptosis has also been demonstrated by showing that siRNA-
induced downregulation of cathepsin D in HeLa and U937 cells confers protection 
against cell death induced by chemotherapy drugs.  The goal of experiments described in 
this chapter was to explore potential mechanistic roles for cathepsin D during 
chemotherapy-induced apoptosis.  VP-16 was used in these studies because it efficiently 
induces cell death in both HeLa and U937 cells and because HeLa and U937 cells 
harboring cathepsin D 144 siRNA were significantly protected against VP-16-induced 
cell death. 
VP-16 induces DNA damage to cells by promoting production of irreversible 
DNA-binding derivatives from oxidation reduction reactions [105, 106] and by inhibiting 
topoisomerase II [151].  As discussed previously, DNA damage initiates the intrinsic 
apoptotic pathway, promoting release of mitochondrial apoptogenic proteins such as 
cytochrome c and SMAC, formation of the apoptosome, and activation of caspase-9 [8, 
22].    
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In preliminary studies, I found that 2 µM VP-16 treatment of U937 cells or 100 
µM VP-16 treatment of HeLa cells efficiently induced 80-90% cell death over a 48-hour 
period.  This chapter provides demonstration that cathepsin D downregulation impacts 
well-characterized apoptotic processes during chemotherapy-induced cell death, 
including mitochondrial release of cytochrome c and the activation of caspase proteases.  
Furthermore, evidence is provided that cathepsin D enzyme acts via a cytosolic factor to 
provoke cytochrome c release in a cell-free system.  In this chapter, I propose a model for 
the mechanistic role of cathepsin D in chemotherapy-induced apoptosis. 
 
5.2. RESULTS 
5.2.1. DOWNREGULATION  OF  CATHEPSIN D  INHIBITS  CASPASE-3  
 ACTIVATION 
The activation of caspase-3 is a critical step in the apoptotic execution of 
chemotherapy-treated U937 cells [26, 152, 153].  Moreover, inhibition of caspase-3 with 
the pharmacologic inhibitor DEVD-FMK almost completely attenuated VP-16-induced 
cell death in wild-type HeLa cells (Figure 5.1.A).  In the relocalization studies described 
in Chapter 3, cathepsin D was shown to be released into the cytosol of U937 cells 
approximately 4 hours after treatment with 2 µM VP-16 (Figure 3.5).  VP-16-induced 
activation of caspase-3 was first observed 8 hours following treatment, as detected by 
immunoblotting (Figure 3.8).  It is possible then, that cathepsin D may act to either 
directly or indirectly activate caspase-3 in chemotherapy-induced apoptosis.  To 
determine whether cathepsin D is important for VP-16-induced caspase-3 activation,
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Figure  5.1.  Downregulation of cathepsin D inhibits caspase-3 activation.  A, Wild-
type HeLa cells were pretreated in the presence or absence of 50 µM DEVD-FMK for 1 
hour prior to treatment with 100 µM VP-16.  Cells were harvested at varying time points, 
and trypan blue exclusion assays were performed to assess cell viability.  DEVD-FMK 
prevented VP-16-induced cell death.  B, Wild-type HeLa cells and 144 CD siRNA/HeLa 
cells were treated with 100 µM VP-16 for varying times.  Whole cell lysates were 
prepared and assessed for caspase-3 activity by measuring cleavage of the caspase-3 
fluorogenic substrate Ac-DEVD-AFC.  Caspase-3 activation was inhibited in HeLa cells 
that express the 144 CD siRNA. C,  Wild-type U937 cells and 144 CD siRNA/U937 cells 
were treated with 2 µM VP-16 for varying times.  Whole cell lysates were prepared and 
caspase-3 activity was measured by cleavage of the caspase-3 substrate.  Caspase-3 
activation was inhibited in U937 cells that express 144 CD siRNA.  Error bars represent 
the standard deviations of triplicate wells. 
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wild-type U937 cells and 144 CD siRNA/U937 cells were treated with 2 µM VP-16 for 
varying lengths of time.  Similarly, wild-type HeLa cells and 144 CD siRNA/HeLa cells 
were treated with 100 µM VP-16.  Whole cell lysates were then prepared and caspase-3 
enzymatic activity in the lysates was assessed by incubating the lysates with the caspase-
3 fluorogenic substrate Ac-DEVD-AFC and measuring cleavage of the substrate by 
spectrofluorometry.  Similar to what was seen in Chapter 3, caspase-3 activation was first 
detected in wild-type HeLa and U937 cells around 8 hours after VP-16 treatment and 
levels continued to increase up to 24 hours.  Caspase-3 activation in cells expressing the 
control siRNA was similar to corresponding wild-type HeLa or U937 cells (data not 
shown).   Importantly, caspase-3 activation was significantly reduced in 144 CD 
siRNA/HeLa cells and 144 CD siRNA/U937 cells (Figure 5.1.B,C).  These data 
suggested that cathepsin D is important for caspase-3 activation during VP-16-induced 
cell death.   
To test whether cathepsin D has the potential to directly activate caspase-3, whole 
cell lysates were prepared from U937 cells and incubated with either 2 µg cathepsin D or 
0.2 µg caspase-3 in the presence or absence of 50 µM z-VAD for one hour at 37 °C.  
Caspase-3 activity in the lysates was measured by cleavage of the fluorogenic caspase 
substrate Ac-DEVD-AFC.  Addition of recombinant caspase-3 to lysates resulted in 
marked cleavage of the caspase-3 substrate, which was completely inhibited by z-VAD-
FMK (Figure 5.2).  However, no increase in caspase-3 activity was noted in cathepsin D-
treated lysates.  The fact that cathepsin D failed to induce rapid activation of caspase-3 
suggests that cathepsin D indirectly promotes caspase-3 activation during chemotherapy-
induced apoptosis or requires some cofactor that is inactivated in extracts.   
 103
  
 
 
 
 
 
Figure  5.2.  Cathepsin D does not directly activate caspase-3.  Whole cell lysates were 
prepared from 5 x 105 wild-type U937 cells.  Cell lysates were treated with 2 µg 
cathepsin D or 0.2 µg caspase-3 at 37 °C for one hour in the presence or absence of the 
pancaspase inhibitor z-VAD-FMK (50 µM).  Caspase-3 activity was assessed by 
measuring cleavage of the caspase-3 fluorogenic substrate Ac-DEVD-AFC.  Caspase-3 
activity was completely inhibited by z-VAD-FMK.  Cathepsin D does not induce rapid 
caspase-3 activation in U937 cell lysates. 
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 5.2.2. DOWNREGULATION  OF  CATHEPSIN D  INHIBITS  CYTOCHROME  
 C  RELEASE 
In addition to performing experiments to assess the impact of cathepsin D 
downregulation on caspase-3 activation, we investigated the upstream apoptotic process 
of cytochrome c release.  As discussed earlier, release of cytochrome c from the 
mitochondria results in formation of the apoptosome complex, activation of caspase-9, 
and subsequent activation of caspase-3.  To investigate the importance of cathepsin D in 
cytochrome c release during chemotherapy treatment, wild-type U937 cells and 144 CD 
siRNA/U937 cells were treated with 2 µM VP-16 for varying lengths of time.  Cytosolic 
fractions were then prepared as described in Materials and Methods, and aliquots of the 
cytosolic proteins (25 µg/lane) were electrophoresed on a 13% SDS-PAGE gel.  The 
Western blot for cytochrome c in Figure 5.3 illustrates the kinetics of cytosolic 
cytochrome c release in both wild-type U937 cells and 144 CD siRNA/U937 cells.  
Cytochrome c was first detected in the cytosol approximately 8 hours after VP-16 
treatment in wild-type cells, but was not detected in 144 CD siRNA/U937 cells until 16 
hours following drug treatment.  Even after 16 or 24 hours, the degree of cytochrome c 
release was reduced in cells expressing the 144 CD siRNA compared to cells expressing 
the control siRNA.  Immunoblotting for cytochrome c oxidase IV showed that cytosolic 
fractions were not contaminated with mitochondria, nor was there general mitochondrial 
rupture or leakage.  Therefore, the observed cytochrome c release was due to VP-16-
induced activation of the intrinsic apoptosis pathway.  Together, these data illustrate that  
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Figure  5.3.  Cathepsin D downregulation inhibits cytochrome c release.  Control 
siRNA/U937 cells or 144 CD siRNA/U937 cells were treated for varying lengths of time 
with 2 µM VP-16.  At the indicated times, cytosolic fractions were prepared from 20 x 
106 cells.  Cytosol was immunoblotted for the appearance of cytochrome c.  Cytochrome 
c was first detected in the cytosol at 8 hours, and markedly increased by 16 hours 
following VP-16 treatment.  Cytochrome c release was inhibited in 144 CD siRNA/U937 
cells up to 24 hours after VP-16 treatment.  Densitometry of the immunoblot was 
analyzed as the ratio of cytochrome c to β-actin.  Immunoblotting with cytochrome c 
oxidase IV was used to verify mitochondrial integrity.  The above immunoblot is 
representative of repeated experiments with similar results. 
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cathepsin D is important for the release of cytochrome c into the cytosol following VP-16 
treatment in U937 cells. 
 
5.2.3. CATHEPSIN D  INDUCES  RELEASE  OF  CYTOCHROME C  FROM   
    ISOLATED MITOCHONDRIA  
 
In the preceding section, I have demonstrated that cathepsin D is important for the 
timely release of cytochrome c and activation of caspases following chemotherapy 
treatment.  To determine whether purified cathepsin D can initiate direct release of 
cytochrome c, isolated mitochondria were treated with purified cathepsin D in a cell-free 
system.  Mitochondrial fractions were isolated from 20 x 106 untreated wild-type U937 
cells using the fractionation protocol described in Materials and Methods.  Mitochondria 
(50 µg) were then treated with 2 µg of cathepsin D for 1 hour at 37 °C, followed by 
centrifugation at 14,000 rpm for 30 minutes at 4 °C to pellet the mitochondria.  
Supernatants, which contained proteins released from the mitochondria, were centrifuged 
twice more at 14,000 rpm for 30 minutes at 4 °C.  The purified supernatants were 
electrophoresed on a 13% SDS-PAGE gel and immunoblotted for cytochrome c.  As 
shown in Figure 5.4, cathepsin D enzyme provoked a modest release of cytochrome c 
into the supernatant, an action that was inhibited by 100 µM pepstatin A.   
Though cathepsin D alone did induce some cytochrome c release, the amount of 
protein released was not markedly different than control.  It was questionable whether 
this level of cytochrome c release could initiate a substantial apoptotic response or 
whether some degree of cytosolic contamination might falsely enhance cathepsin D-
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Figure  5.4.  Cathepsin D induces release of cytochrome c from isolated 
mitochondria.  Mitochondria were isolated from wild-type U937 cells as described in 
Materials and Methods. Mitochondria (50 µg) were then treated with 2 µg purified 
cathepsin D enzyme for 1 hour at 37 °C in the presence or absence of 100 µM pepstatin 
A. Supernatants were isolated by centrifugation and immunoblotted for cytochrome c.  
Cathepsin D elicits release of cytochrome c from mitochondria that is completely 
inhibited by pepstatin A. 
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induced cytochrome c release.  To examine whether cytosolic proteins might enhance 
cathepsin D-mediated cytochrome c release, mitochondrial and cytosolic extracts were 
prepared from untreated wild-type U937 cells.  Mitochondria (50 µg) were then 
incubated with 2 µg cathepsin D in the presence or absence of 10 µg cytosolic extract.  
Following incubation, supernatants were purified, electrophoresed on a 13% SDS-PAGE 
gel, and immunoblotted for cytochrome c.  As shown in Figure 5.4, cathepsin D alone 
was again found to provoke only a modest release of cytochrome c from mitochondria.  
However, mitochondria that were incubated with cathepsin D in the presence of cytosolic 
extracts exhibited robust release of cytochrome c (> 25-fold) relative to mitochondria 
incubated with cathepsin D alone, as shown by densitometric scanning of the immunoblot 
(Figure 5.5).  This release of cytochrome c was completely inhibited by 100 µM pepstatin 
A, demonstrating that the release was due to cathepsin D enzymatic activity.  These 
results suggest that cathepsin D cleaves a cytosolic factor, which then mediates the 
effects of cathepsin D on cytochrome c release. 
 
5.2.4. DOWNREGULATION  OF  CATHEPSIN D  INHIBITS  SMAC/DIABLO  
 RELEASE 
If cathepsin D plays a role in cytochrome c release during chemotherapy-induced 
apoptosis, it also may play a role in the release of other apoptogenic mitochondrial 
proteins as well.  The proapoptotic factor, SMAC/Diablo, is known to be released from 
mitochondria during chemotherapy-induced apoptosis, where it enhances caspase activity 
by binding and inactivating caspase inhibitory proteins in the Inhibitor of Apoptosis 
protein family (IAPs), particularly XIAP [154, 155].  To determine whether cathepsin D 
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Figure  5.5.  Cytochrome c release stimulated by cathepsin D is enhanced by the 
presence of cytosolic extracts.  Mitochondrial and cytosolic fractions were isolated from 
wild-type U937 cells as described in Materials and Methods.  Mitochondria (50 µg) were 
then incubated for 1 hour at 37 ºC with 10 µg of cytosol (Lane 2), 2 µg cathepsin D alone 
(Lane 3), or cytosol preincubated with cathepsin D for 1 minute (Lane 4).  Supernatants 
were isolated by centrifugation and probed for the presence of cytochrome c.  Although 
cathepsin D alone induced a small amount of cytochrome c release, incubation of 
cathepsin D with cytosol robustly enhanced cytochrome c release.  The release of 
cytochrome c was completely inhibited by 100 µM pepstatin A.  Densitometry represents 
the fold increase of cytochrome c release relative to untreated mitochondria. 
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 impacts the cytosolic release of SMAC during chemotherapy treatment, wild-type U937 
cells and 144 CD siRNA/U937 cells were treated with 2 µM VP-16, and cytosolic 
fractions were prepared at varying time points.  Cytosolic proteins (25 µg/lane) were then 
electrophoresed on a 13% SDS-PAGE gel, and subjected to immunoblotting with anti-
SMAC.  Figure 5.6 shows that the release of SMAC into the cytosol in U937 cells 
expressing control siRNA was first detected at 16 hours. By contrast, no release of 
SMAC was detected in 144 CD siRNA/U937 cells, even after 24 hours of VP-16 
treatment.  These data suggest that cathepsin D can enhance the activation of caspases 
during chemotherapy treatment by stimulating not only release of cytochrome c, but also 
release of SMAC from mitochondria, thus perhaps relieving caspases from IAP 
inhibition.  
 
5.2.5. CATHEPSIN D-INDUCED  CYTOCHROME C  RELEASE  IS  NOT  
 DEPENDENT  ON  CASPASES 
The data thus far have determined that cathepsin D acts on a cytosolic factor to 
promote cytochrome c release.  Though cathepsin D does not activate caspase-3 through 
direct cleavage (Figure 5.2), it may promote caspase activation by prompting cytochrome 
c and SMAC release.  Although caspase activation typically occurs downstream of 
cytochrome c release, it has been reported that the release of cytochrome c may occur in 
2 stages [17, 130].   Following an initial release, caspase-3 becomes activated.  Activated 
caspase-3 may then act in a positive feedback amplification loop to promote additional 
cytochrome c release [17, 130].  To investigate whether caspases are necessary for 
cathepsin D-induced cytochrome c release, mitochondrial and cytosolic fractions were 
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Figure  5.6.  Cathepsin D siRNA inhibits SMAC/Diablo release.  Control siRNA/U937 
cells and 144 CD siRNA/U937 cells were treated with 2 µM VP-16 for varying lengths of 
time and cytosolic extracts were prepared as described in Materials and Methods.  
Cytosolic proteins (25 µg/lane) were immunblotted to detect release of cytochrome c.  
SMAC was released from control siRNA/U937 cells 16 hours after VP-16 treatment, but 
release was inhibited dramatically in 144 CD siRNA/U937 cells.   
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isolated from wild-type U937 cells.  Mitochondria (50 µg) and cytosolic extracts (10 µg) 
were then preincubated with caspase-3 inhibitor (50 µM z-VAD-FMK) or cathepsin D 
inhibitor (100 µM pepstatin A) for 5 minutes prior to addition of 2 µg cathepsin D 
enzyme.  In the presence of cytosol, cathepsin D promoted substantial release of 
cytochrome c from mitochondria (Figure 5.7).  Cathepsin D-mediated cytochrome c 
release was completely inhibited by pepstatin A, but was unaffected by the caspase 
inhibitor.  Therefore, caspases do not appear to mediate the effects of cathepsin D on 
cytochrome c release. 
The effects of cysteine cathepsin inhibitors on cathepsin D-mediated cytochrome c 
release were also examined.  Isolated mitochondria and cytosolic extracts were pretreated 
with cathepsin B inhibitor (50 µM z-FA-FMK) or cathepsin L inhibitor (50 µM z-FF-
FMK) for 5 minutes prior to addition of 2 µg cathepsin D (Figure 5.7).  As expected, 
cathepsin B inhibition had no effect on cathepsin D-induced cytochrome c release.  
Unexpectedly, inhibition of cathepsin L resulted in a 50% reduction in cathepsin D-
induced cytochrome c release.  This data opens up the possibility that cathepsin L may 
act as an intermediary factor in cathepsin D-induced cytochrome c release.  This issue 
will be addressed further in the discussion. 
 
5.3. DISCUSSION 
The data in this chapter have shown that caspase activation and cytochrome c 
release, as well as SMAC release, are inhibited by siRNA-mediated downregulation of 
cathepsin D during chemotherapy-induced apoptosis.  I propose a model in which 
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Figure  5.7.  Impact of pharmacologic enzyme inhibitors on cathepsin D-induced cytochrome c release.  Mitochondria and 
cytosol were isolated from untreated wild-type U937 cells and treated with 2 µg cathepsin D in the presence of 100 µM pepstatin A, 
50 µM z-VAD-FMK (pancaspase inhibitor), 50 µM z-IETD-FMK (caspase-8 inhibitor), 50 µM cathepsin B inhibitor, or 50 µM 
cathepsin L inhibitor.  Following incubation for 1 hour at 37 °C, reactions were centrifuged and the supernatants were subjected to 
immunoblotting to detect release of cytochrome c.  Cathepsin D-induced cytochrome c release was inhibited by pepstatin A, but not 
by caspase inhibitors z-VAD or z-IETD.  Cathepsin B inhibitor (50 µM z-FA) had no impact on cathepsin D-induced cytochrome c 
release.  By contrast, cathepsin L inhibitor (50 µM z-FF) inhibited cytochrome c release by almost 50% (densitometric scanning, not 
shown). 
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chemotherapy drugs initiate release of cathepsin D into the cytosol.  I hypothesize that in 
the cytosol, cathepsin D cleaves a cytosolic factor to provoke cytochrome c release and 
subsequent caspase activation (Figure 5.8).  While identification of this factor is beyond 
the scope of this project, some possibilities will be discussed.   
Though cytochrome c release typically precedes caspase-3 activation, it has been 
shown that only a small amount of cytochrome c is initially released [17, 130].  Figure 
5.3 also showed that the initial release of cytochrome c at 8 hours was not substantial.  
Formation of the apoptosome following cytochrome c release initiates activation of 
caspase-9, which is followed soon thereafter by activation of caspase-3.  Chen et al. [17] 
demonstrated that, following VP-16 treatment, active caspase-3 acts in an amplification 
loop to induce additional loss of mitochondrial potential and massive release of 
cytochrome c.  It was possible, therefore, that cathepsin D cleavage of caspases may lead 
to a large-scale release of cytochrome c.  In Figure 5.7, however, inhibition of caspase-3 
by DEVD-FMK and caspase-8 by IETD-FMK had no effect on cathepsin D-induced 
cytochrome c release. Additionally, cathepsin D was not able to rapidly activate caspase-
3 (Figure 5.2) or caspase-8 (not shown).  Therefore, caspases do not appear to be 
cytosolic intermediates of cathepsin D-induced cytochrome c release.      
The effects of cysteine cathepsin inhibitors on cathepsin D-induced cytochrome c 
release from isolated mitochondria were also assessed.  In previous experiments, I had 
shown that cathepsin B remained in the lysosomes during the course of VP-16 treatment 
(Figure 3.7).  As expected, inhibition of cathepsin B had no impact on cathepsin D-
induced cytochrome release (Figure 5.7).  Cathepsin B has been implicated in apoptosis 
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Figure  5.8.  Potential mechanism of cathepsin D action.     denotes cleavage or activation.  See text for details.
induced by the death ligand TNF-α and by microtubule-stabilizing agents, but there is no 
evidence to suggest that cathepsin B is important for chemotherapy-induced apoptosis 
[64, 67-69].  Investigations of cathepsin L in apoptosis are contradictory.  Levicar et al. 
[156] found that cathepsin L upregulation was associated with reduced apoptosis.  
Additionally, antisense-mediated downregulation of cathepsin L sensitized cells to 
apoptosis by reducing expression of the antiapoptotic protein Bcl-2, suggesting that 
cathepsin L might have an antiapoptotic effect.  In another study, cathepsin L-deficient 
A549 cells displayed increased sensitivity to apoptosis [157].  In contrast, Ishisaka et al. 
[77] found that caspase-3 cleavage in cytosolic extracts by a crude lysosomal fraction 
was inhibited by two specific cathepsin L inhibitors, suggesting that cathepsin L might 
contribute to the apoptotic process.  In this project, cathepsin D-induced cytochrome c 
release from isolated mitochondria was reduced by about 50% with the cathepsin L 
inhibitor z-FF-FMK (50 µM) (Figure 5.7).  If cathepsin L is released from lysosomes 
following VP-16 treatment, it could potentially act as an intermediary for cathepsin D-
induced cytochrome c release.  The non-specificity of cathepsin L antibodies precluded 
study of the localization of cathepsin L following chemotherapy drug treatment in my 
project, but others have shown that it is released from the lysosomes during oxidative 
stress- and supraoptimal activation-induced apoptosis [60, 98, 158].  If cathepsin D is 
released following disruption of lysosomal targeting motifs, as suggested in Chapter 3, it 
would not be surprising to note mutual relocalization of cathepsin L and cathepsin D, as 
they both contain similar targeting motifs [79].  Inhibition of cathepsin L prevented 
cathepsin D-mediated cytochrome c release; therefore, it is possible that cathepsin D 
cleaves cathepsin L following cytosolic relocalization of both enzymes and the cleaved 
cathepsin L serves to mediate cytochrome c release.   
Another possible mediator of cathepsin D action is the proapoptotic Bcl-2 family 
member Bid.  Bid resides in the cytoplasm as an inactive 26 kD protein.  Following 
specific apoptotic stimuli, Bid is cleaved to a 15 kD truncated form (tBid), and this 
truncated form translocates to the mitochondria to provoke cytochrome c release [117, 
159, 160].  Bid is normally activated by the death-receptor pathway in response to stimuli 
such as TNF-α or Fas ligand, but it can be activated by some drugs as well [161].  Thus, 
it can act as a “bridge” between the death-receptor mediated cell death pathway and the 
intrinsic mitochondrial pathway [162].  Reports on the role of lysosomal proteases in Bid 
cleavage are incongruous.  A recent study demonstrated that disruption of lysosomes in 
HeLa cells, resulting in translocation of lysosomal proteases to the cytosol, initiated the 
cleavage of Bid [163].  Likewise, extracts of purified lysosomes were found to process 
Bid to an active fragment in vitro [57, 62].  Additionally, mitochondria that were 
incubated with Bid that had been treated with lysosomal extracts released a significant 
amount of cytochrome c.  By contrast, mitochondria did not release cytochrome c in 
response to Bid-deficient cytosolic extract that had been incubated with lysosomal 
extract. [57].  Cirman et al. [163] reported that cathepsins B, H, L, and S can cleave Bid 
in vitro and that incubation of Bid with these cathepsins initiated rapid cytochrome c 
release from isolated mitochondria.  However, Reiners et al. [62] and Mandic et al. [164] 
found that pharmacologic inhibition of cathepsins B, D, and L failed to suppress Bid 
cleavage following lysosomal photodamage.  Another study showed that cystatin B-
deficiency-induced apoptosis, which is promoted by cathepsins, was unaffected in Bid-
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deficient mice, suggesting that cathepsins can promote apoptosis via a Bid-independent 
mechanism [165].   
Likewise, data examining the importance of Bid in cathepsin D-induced apoptosis 
is also conflicting.  In a recent study, Bid was reported to be cleaved to tBid by purified 
cathepsin D in vitro [149].  Moreover, in another study, Bid was not activated in 
cathepsin D-deficient fibroblasts during TNF-α-induced apoptosis [149].  However, most 
reports have demonstrated that cathepsin D cannot directly cleave Bid in vitro or in vivo 
[62, 163, 166].  Cathepsin D preferentially cleaves dipeptide bonds between hydrophobic 
residues, and Bid contains no sequences which are compatible with this stipulation [167].  
With this in mind, investigations on the importance of cathepsin D in Bid cleavage are 
currently ongoing.   
Because inadvertent activation of caspases would prove disastrous to healthy 
cells, regulation of caspase activation is stringent.  Several safeguards must be 
surmounted before caspases are fully activated during the apoptotic process.  
SMAC/Diablo is a 25 kD protein that is released from the mitochondria during apoptosis 
and binds to IAP (Inhibitor-of-APoptosis) family members [154, 168].  IAPs, particularly 
XIAP, inhibit caspase activation by binding to the active pocket of several caspase 
enzymes, thereby preventing substrate entry [154, 169, 170].  When SMAC/Diablo is 
released into the cytosol during apoptosis, it binds to XIAP and “peels” it away from 
caspases, exposing their active site [155].  The importance of cathepsin D for SMAC 
release into the cytosol following chemotherapy treatment was examined by comparing 
the kinetics of cytosolic SMAC appearance in wild-type U937 cells and 144 CD 
siRNA/U937 cells.  VP-16-induced release of SMAC/Diablo was inhibited in 144 CD 
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siRNA/U937 cells.  Though purified cathepsin D did not induce direct activation of 
caspase-3 in vitro (Figure 5.2), cathepsin D-downregulation in U937 cells did impact 
caspase-3 activation in whole cells (Figure 5.1).  It is possible, therefore, that in addition 
to stimulating release of cytochrome c, cathepsin D potentiates caspase-3 activation by 
augmenting release of SMAC/Diablo from the mitochondria and promoting liberation of 
caspases from IAP inhibition.   
We have not yet identified the mediator responsible for cathepsin D-induced 
cytochrome c release.  Preliminary experiments suggest that Bid cleavage is unaffected in 
VP-16-treated CD siRNA cells; therefore, other candidates must also be considered.  
Recent studies have demonstrated that during VP-16-induced apoptosis, the nuclear 
histone H1.2 is released into the cytoplasm, where it stimulates cytochrome c release in a 
Bak-dependent/Bid-independent manner [171].  Bak is a 23 kD pro-apoptotic member of 
the Bcl-2 family that is normally activated by tBid.  Bak contributes to apoptosis by 
oligomerizing and forming pores that contribute to mitochondrial membrane 
permeabilization [172, 173].  Wei et al. [174] have shown that VP-16 induces apoptosis 
in Bid-deficient mouse embryonic fibroblasts (MEFs), but that Bak is still activated and 
is absolutely necessary for cell death.  In non-apoptotic cells, Bak is sequestered in an 
inactive form by the antiapoptotic protein Bcl-XL in the cytosol [175].  Activation of Bcl-
XL occurs via cleavage of the full-length protein into an 18 kD fragment [176].  
Therefore, if cathepsin D perhaps cleaves Bcl-XL protein, causing release of Bak, Bcl-XL 
may represent another potential intermediate of cathepsin D-induced cytochrome c 
release.   
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An alternate possibility of cathepsin D action during VP-16-induced apoptosis is 
that a cytosolic factor may initiate supraoptimal activation of the cathepsin D enzyme to 
induce cytochrome c release.  Experiments in which cytosolic extracts are incubated with 
pepstatin A either before  or after addition of the cathepsin D enzyme would determine 
whether this unknown factor acts upstream or downstream of cathepsin D action in 
cytochrome c release following VP-16 treatment. 
 
5.4. CONCLUSION 
In this chapter, I have demonstrated that cathepsin D mediates cytochrome c 
release and caspase-3 activation following VP-16 treatment.  Additionally, cathepsin 
D-cleaved cytosolic extract induces cytochrome c release from isolated 
mitochondria, suggesting that cathepsin D cleavage of a cytosolic factor is likely 
important for promoting cytochrome c release in cells.  Moreover, cathepsin D may 
enhance the release of proapoptotic SMAC into the cytosol during chemotherapy-
induced apoptosis, perhaps further augmenting caspase activation.   
 
5.5. FINAL STATEMENT 
Cell lines containing siRNA directed against cathepsin D mRNA were protected 
from chemotherapy-induced cell death, but cell death was not completely attenuated.  
Most likely, cathepsin D promotes chemotherapy-induced cell death by accelerating and 
augmenting various key apoptotic processes.  The importance of understanding the 
mechanism of cathepsin D action in apoptosis should not be underestimated.  Current 
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chemotherapy strategies are plagued by problems with cytotoxicity in normal cells and 
with acquired resistance, which leads to reduced therapeutic potential.  Cytotoxic 
responses develop when chemotherapy drugs reduce expression or function of a target 
protein that, while contributing to the neoplastic potential of one cell, is vital to the 
normal function of another.  The development of novel drug targets and targeting 
strategies is critically important for circumventing the resistance and cytotoxic problems 
incurred with current drugs and targets.  With its ability to significantly enhance 
chemotherapeutic drug-induced cell death, cathepsin D and the pathway it mediates may 
represent a novel therapeutic target for combinatorial anti-cancer strategies.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 122
APPENDICES
 123
 APPENDIX A 
 
ABBREVIATIONS 
 
AIF……………................... Apoptosis-inducing factor 
Apaf-1…………………….. Apoptotic protease activating factor 
ATP……………………….. Adenosine triphosphate 
CB………………………… Cathepsin B 
CD………………………... Cathepsin D   
DD………………………... Death domain 
DED………………………. Death effector domain 
DISC……………………… Death-inducing signaling complex 
DMSO……………………. Dimethyl sulfoxide 
DR………………………... Death receptor 
dsRNA……………………. Double-stranded RNA 
DTT………………………. Dithiothreitol 
ECV………………………. Endosomal carrier vehicles 
EDTA…………………….. Ethylenediaminetetraacetic acid 
FADD…………………….. Fas-associated protein with death domain 
IFN-γ……………………… Interferon-γ 
LAMP…………………….. Lysosome-associated membrane protein 
M6P………………………. Mannose-6-phosphate 
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MEF………………………. Mouse embryonic fibroblast 
MSA……………………… Microtubule stabilizing agent 
PARP……………………... Poly-ADP-ribose polymerase 
PBS……………………….. Phosphate-buffered saline 
PCD………………………. Programmed cell death 
PKC………………………. Protein kinase C 
PMSF……………………... Phenyl methane sulphonyl fluoride 
RISC………………………. RNA-induced signaling complex 
RNAi………………………. RNA interference 
SDS-PAGE………………... Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
siRNA……………………... Small-interfering RNA 
TBST……………………… Tris-buffered saline + Tween-20 
TNF-α…………………….. Tumor necrosis factor-α 
TNFR……………………… Tumor necrosis factor receptor 
TRADD…………………… TNF receptor-associated protein with death domain 
TRAIL…………………….. TNF-related apoptosis-inducing ligand 
WT………………………... Wild-type 
XIAP……………………… X-linked inhibitor of apoptosis protein 
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 APPENDIX B 
 
ANTIBODIES 
 
Antibody 
name (anti-) Type 
Primary Antibody 
Dilution 
Secondary Antibody 
Dilution Company 
β-actin Mouse 1:5000 1:5000 Sigma 
Caspase-3 Rabbit 1:1000 1:4000 Cell Signaling 
Caspase-8 Mouse 1:1000 1:4000 Cell Signaling 
Cathepsin B Rabbit 1:250 1:4000 Calbiochem 
Cathepsin D Rabbit 1:1000 1:4000 Calbiochem 
Cathepsin E Goat 1:1000 1:4000 Santa Cruz 
Cytochrome c Mouse 1:1000 1:4000 BD Pharmingen 
Cytochrome c 
oxidase IV Mouse 1:1000 1:4000 Molecular Probes 
LAMP Mouse 1:1000 1:4000 RDI 
PARP Mouse 1:1000 1:4000 BD Pharmingen 
SMAC Goat 1:1000 1:4000 R&D Systems 
XIAP Mouse 1:1000 1:4000 BD Transduction 
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 APPENDIX C 
 
ENZYME SUBSTRATES 
 
Enzyme Name Enzyme Substrate 
β-hexosaminidase 4-methylumberriferyl-N-acetyl-β-D-glucosaminide 
Caspase-3 Ac-DEVD-AFC 
Cathepsin D MoCAc-Gly-Lys-Pro-Ile-Phe-Phe-Arg-Leu(Dnp)-D-Arg-NH2 
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